

1 **A conserved helix-tiling architecture of urate oxidase organizes metabolism in**
2 **peroxisomes**

3

4 Junhan Yang^{1, *}, Zhe Chen^{1, *}, Yonglun Wang^{2, *}, Zibo Yu¹, Sihao Yuan³, Xiao Sun^{4, 5},
5 Chuanwen Kan^{4, 5}, Wenjing Du¹, Zhixun Li¹, Shenjia Luo¹, Yuan'gang Zhu², Xinyang
6 Shao^{6, 7}, Guanbo Wang⁶, Mingkun Li^{4, 5}, Yiqin Gao³, Xiaowei Chen^{2, #}, Qiang Guo^{1, 7, #}.

7

8

9 ¹State Key Laboratory of Membrane Biology, Peking-Tsinghua Joint Center for Life
10 Sciences, Scholar of Life Sciences, Peking University, Beijing 100871, China

11 ²State Key Laboratory of Membrane Biology and Institute of Molecular Medicine,
12 College of Future Technology, Peking University, Beijing 100871, China

13 ³College of Chemistry and Molecular Engineering, Peking University, Beijing 100871,
14 China

15 ⁴Beijing Institute of Genomics, Chinese Academy of Sciences, and China National
16 Center for Bioinformation, Beijing, China

17 ⁵University of Chinese Academy of Sciences, Beijing, China

18 ⁶Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing
19 100871, China

20 ⁷Changping Laboratory, Beijing 102206, China

21

22

23 * Equal contribution

24 # Co-correspondence

25 Lead contact: guo.qiang@pku.edu.cn

26

27

28 **Abstract**

29 Cells organize metabolism within a crowded intracellular milieu, yet the structural logic
30 and functional consequences of supramolecular enzyme assemblies *in vivo* remain
31 poorly defined. Here, using *in situ* cryo-electron tomography, we identify a previously
32 uncharacterized high-order architecture of urate oxidase in mouse liver. Urate oxidase
33 homotetramers assemble into helical fibers that tile laterally to form a stable, and porous
34 lamellar scaffold. This organization preserves extensive accessible surface area while
35 permitting efficient substrate and product exchange. Structure-guided perturbation
36 abolishes the assembly *in vivo* without measurably altering intrinsic catalytic activity,
37 indicating a primary role in spatial organization rather than allosteric regulation.
38 Consistent with this, the assembled state enhances resistance to thermal, proteolytic and
39 oxidative stress, supporting sustained activity in the peroxide-rich peroxisomal matrix.
40 Conserved across mammals, this architecture reveals a strategy for metabolic
41 compartmentalization that couples efficient catalysis to increased molecular robustness
42 without the trade-off between supramolecular assembly and enzyme accessibility.

43

44

45 **Introduction**

46 The biochemical landscape of living cells fundamentally differs from dilute *in vitro*
47 systems due to extreme macromolecular crowding, in which proteins and other
48 macromolecules occupy approximately 15-30% of the intracellular volume ^{1,2}. This
49 dense environment reshapes the thermodynamics and kinetics of biological processes,
50 altering molecular diffusion, interaction equilibria, and effective reaction rates ³⁻⁶.
51 Consequently, cellular biochemistry operates under physical constraints that cannot be
52 inferred from dilute systems alone. Rather than constituting a simple "bag of
53 macromolecules", the intracellular milieu exhibits sophisticated organizational
54 principles that have evolved to optimize biochemical processes under these constraints
55 ⁷. Understanding these principles in their native context is essential, as both structure
56 and function emerge from coupled effects of crowding and cellular regulation that
57 cannot be fully reconstituted in purified systems.

58

59 Cells employ diverse compartmentalization strategies to organize their crowded interior,
60 with the resulting physical state determined by the strength and specificity of
61 intermolecular interactions. Weak, multivalent interactions drive liquid-liquid phase
62 separation, forming dynamic biomolecular condensates ^{8,9}. These membraneless
63 organelles serve critical functions including concentrating specific enzymes to enhance
64 reactions, organizing chromatin to regulate gene expression, and sequestering damaged
65 proteins during cellular stress ^{10,11}. In contrast, strong and specific interactions give rise
66 to stable solid-like assemblies, including amyloid aggregates ¹² and crystalline
67 inclusions ¹³, such as insulin in pancreatic β -cell secretory granules or yeast proteasome
68 storage granules, which primarily function as inactive molecular storage ^{14,15}.

69

70 These organizational states exist along a dynamic continuum, with many systems
71 exhibiting stimulus-responsive interconversion ¹⁶. Metabolic enzymes exemplify this
72 plasticity, assembling into liquid-like condensates filaments or other high-order
73 structures in response to changes in cellular metabolic state ¹⁷⁻²⁰. Increasingly, such
74 assemblies are understood not to enhance intrinsic catalytic chemistry, but to act

75 through spatial organization—modulating effective diffusion distances, local
76 concentrations, and enzyme stability in crowded environments ⁶. Recent discoveries
77 have further expanded this paradigm, revealing unexpected organizational
78 geometries—including fractal assemblies observed *in vivo*, though their functional
79 significance remains enigmatic ²¹. Together, these observations highlight the need to
80 characterize novel molecular assemblies that integrate catalytic activity with non-
81 canonical high-order organization in native cellular contexts.

82

83 Advances in cryo-electron tomography now enable structural characterization of these
84 assemblies at molecular resolution within cells, frequently revealing architectures and
85 functional states divergent from those observed *in vitro* ²². Here, we report the discovery
86 of a previously uncharacterized supramolecular assembly within peroxisomes of mouse
87 liver tissue. We identify its molecular composition, resolve its high-order architecture,
88 define its assembly mechanism, assess its enzymatic properties *in situ*, and establish its
89 evolutionary conservation across mammals. These findings expand our understanding
90 of how cells organize metabolic enzymes in crowded intracellular environments and
91 reveal a distinct principle by which high-order organization supports metabolic function
92 without altering intrinsic catalytic activity.

93

94 **Results**

95 **An uncharacterized supramolecular assembly in mouse hepatic peroxisomes**

96 We leveraged our recently developed workflow to resolve the subcellular architecture
97 of hepatocytes in mouse liver (Supplementary Figure 1a). This approach enabled the
98 visualization of numerous organelles and their inter-organelle interactions, consistent
99 with the central metabolic role of the liver²³. Unexpectedly, we frequently observed a
100 large supramolecular assembly with a distinct periodic pattern within single-membrane-
101 bound organelles (Figure 1a-b, Supplementary Figure 1b-g). This assembly comprised
102 parallel filamentous elements spaced at regular intervals of ~4 or ~8 nm, with the
103 number of filaments ranging from a few to several dozen (Figure 1e-f, Supplementary
104 Figure 1i). In orthogonal views, these elements appeared as hollow tubular densities
105 spaced at ~10 nm and oriented at an angle of ~144° (Figure 1c-d, Supplementary Figure
106 1h). Together, the filaments formed irregularly curved sheet-like structures, as revealed
107 in the three-dimensional segmentation (Figure 1b, Supplementary Figure 1g). To our
108 knowledge, this architecture represents a previously uncharacterized intracellular
109 assembly.

110
111 Organelles containing these assemblies have diameters of around 0.3~0.6 μm (Figure
112 1k). Most harbored one or two such assemblies (Figure 1l), featured a dense lumen, and
113 were frequently encircled by endoplasmic reticulum (Figure 1a, Supplementary Figure
114 1b-f), reminiscent of the hepatocyte-enriched wrappER-peroxisome contact sites²⁴.
115 Based on these morphological features, we identified these organelles as peroxisomes,
116 which are ubiquitous in eukaryotic cells. Previous ultrastructural studies have described
117 a “crystalloid core” in hepatic peroxisomes from several mammalian species²⁵⁻²⁸, and
118 multiple structural models have been proposed^{29,30}, however, none resemble the
119 organization observed in our data.

120
121 To further characterize this assembly, we performed subtomogram averaging to
122 determine its molecular architecture (Supplementary Figure 2a). The fundamental
123 repeating unit consisted of three laterally associated helical fibers, with an overall width

124 of ~ 425 Å (Figure 1g-h). Adjacent fibers exhibited a center-to-center spacing of ~ 115
125 Å and an inter-fiber angle of $\sim 144^\circ$ (Figure 1g-h), in close agreement with
126 measurements directly from tomograms (Figure 1d). Each fiber formed a hollow tube
127 with an inner diameter of ~ 35 Å and an outer diameter of ~ 210 Å, which adopted a
128 right-handed double-helical configuration (Figure 1i-j, Supplementary Figure 3a). The
129 asymmetric unit in each fiber adopted a hollow cylindrical structure with an outer
130 diameter and height of ~ 75 Å. Application of helical symmetry yielded a reconstruction
131 at 7.3 Å resolution for a single fiber, sufficient to resolve secondary structural features
132 (Supplementary Figure 2b-c, Supplementary Table 1).

133

134 To identify the molecular components of the assembly, we retrieved AlphaFold2-
135 predicted structures³¹ of all peroxisomal proteins detected at high frequency by mass
136 spectrometry³². These models were fitted into the density map of asymmetric unit of
137 the fiber using DiffFit³³ and ranked by Q-scores³⁴ (Supplementary Table 2). Urate
138 oxidase (UOX, or uricase) exhibited the highest-scoring fit, supported by strong
139 correspondence between the predicted secondary structural elements and our
140 experimental density map (Supplementary Figure 2d). UOX catalyzes the oxidation of
141 uric acid to 5-hydroxyisourate, an intermediate in purine degradation^{35,36}. It is
142 predominantly expressed in hepatocytes, where it localizes to peroxisomes³⁷⁻³⁹.

143

144 To validate this assignment, we recombinantly expressed and purified mouse UOX and
145 determined its structure *in vitro* using single-particle cryo-electron microscopy,
146 achieving resolutions of 2.79 Å in the apo state and 2.42 Å in the substrate-bound state
147 (Supplementary Figure 4, Supplementary Table 2). The recombinant UOX formed a
148 homotetramer that aligned precisely with the asymmetric unit of the *in situ* fiber (Figure
149 1m). We therefore concluded that the supramolecular assembly in peroxisomes is
150 exclusively composed of UOX, consistent with prior implications of UOX enrichment
151 in the “crystalloid core” of peroxisomes⁴⁰.

152

153 **Molecular basis of the UOX assembly**

154 Although the *in situ* resolution was sufficient to establish the molecular identity of the
155 assembly, elucidating the molecular interactions governing helical fiber formation
156 required higher-resolution structural details. Inspired by recent *ex vivo* structural studies
157 ^{41,42}, we isolated peroxisomes from mouse liver and imaged them to resolve the UOX
158 assembly structure using single-particle cryo-EM approach (Supplementary Figure 5a).
159 The integrity of peroxisomes and native architecture of the UOX assembly were well
160 preserved after isolation, as indicated by identical helical parameters, yielding a
161 reconstruction of the helical fiber at 3.64 Å resolution (Supplementary Figure 5b-c,
162 Supplementary Table 2). This map enabled atomic model building and detailed analysis
163 of the interactions underlying helical assembly.

164

165 To analyze inter-tetramer interactions, each asymmetric unit of the fiber —
166 corresponding to a UOX homotetramer — was assigned a unique index based on the
167 two-start right-handed helical symmetry and computationally "unwound" into two
168 dimensions for visualization (Figure 2a-b, Supplementary Figure 3a). In this scheme,
169 each unit *i* engages six first-shell neighbors: $i \pm 2$, $i \pm 3$, and $i \pm 5$, defining three distinct
170 interaction interfaces (Supplementary Figure 3b). Interface A, formed between units *i*
171 and $i \pm 5$, is stabilized primarily by electrostatic interactions involving Asn123 residues
172 (Figure 2c-d). Interface B, between *i* and $i \pm 3$, lacks obvious stabilizing contacts and is
173 notably positioned adjacent to the catalytic site. Interface C, between *i* and $i \pm 2$, is the
174 most extensive, and drives right-handed helical propagation. This interface features
175 reciprocal electrostatic interactions between Arg202 of unit *i* and Asn148 of unit $i \pm 2$,
176 reflecting the centrosymmetric geometry of the assembly. Additional stabilization arises
177 from potential hydrogen bonds between Arg82 of one tetramer and Ser100/Ser101 of
178 its neighbor (Figure 2e-g), as well as a hydrophobic patch formed by paired Leu81,
179 Leu274, and Ile275 (Figure 2h-i). Together, these findings indicate that Interface C
180 mediates primary helical extension, while Interface A facilitates secondary strand
181 crossover, collectively enabling the observed double-helical architecture.

182

183 Interestingly, the cross-section view of the helical fiber exhibits an apparent fivefold

184 symmetry, which, according to crystallographic restriction theorem, precludes the
185 formation of a space-filling crystal lattice. This observation is consistent with the
186 absence of crystalline blocks and the presence of extended lamellar sheets within
187 peroxisomes. Analysis of inter-fiber contacts uncovered a distinctive lateral
188 propagation mechanism, in which adjacent helical fibers share a column of UOX
189 homotetramers (Figure 3a). The D_2 symmetry of each homotetramer generates four
190 equivalent copies of Interface C, allowing a single fiber to extend laterally in up to five
191 distinct directions. However, steric hindrance at multi-fiber junctions prevents
192 simultaneous extension into immediately adjacent paths, imposing a defined angular
193 constraint (Figure 3b). Iterative application of these geometric rules gives rise to a
194 single-layered, unbranched lamellar architecture within peroxisomes, which we term as
195 "helix tiling assembly" (Figure 3c-d, Supplementary Video 1). In this organization,
196 helical fibers associate laterally while prohibit from forming a continuous, space-filling
197 crystal.

198

199 We conceptualized this hierarchical principle as the "Three Breeds All" model: each
200 helical fiber nucleates two neighbors to form a tripartite unit, which then serves as the
201 fundamental module for propagation of the lamellar network. Consistent with this
202 model, projection of the unmasked subtomogram averaged density map revealed a tree-
203 like fiber pattern with characteristic $\sim 144^\circ$ inter-fiber angles (Fig. 3e). Quantitative
204 mapping of the helical fibers back into original tomograms confirmed this architecture,
205 showing close agreement with our model predictions. On average, individual UOX
206 assembly contained ~ 27 distinct fibers (Fig. 3f).

207

208 **Evolution of the UOX assembly**

209 Our structural data suggest that formation of UOX assembly is primarily governed by
210 Interface C, or several short motifs within it. Consistent with this interpretation, we
211 occasionally observed similar assemblies in recombinant UOX expressed in *E. coli*
212 (Supplementary Figure 6a-b), indicating that the capacity for self-assembly is at least
213 partially intrinsic to the protein. Degradation of purines to uric acid is conserved across

214 metazoans, however, downstream uric acid metabolism varies markedly between
215 species. Most mammals, with the notable exception of human and hominoid primates,
216 express UOX in their liver⁴³. Previous ultrastructural studies of hepatic peroxisomes
217 from diverse mammals have reported the widespread presence of putative UOX-
218 derived crystalloid inclusions, with species-dependent variation in overall morphology
219 observed across mice and other larger mammals, including rats and pigs²⁸.

220

221 Motivated by these observations, we wondered whether the helix tiling assembly is
222 conserved among UOX-expressing mammals. Multiple-sequence alignment of
223 mammalian UOX proteins revealed that residues comprising Interface C are nearly
224 invariant, with only limited substitutions at positions 81, 82, 148, 202 and 275 (Figure
225 4a). Among these, positions 81 and 82 show the greatest divergence in mice relative to
226 other mammals (Figure 4a, Supplementary Figure 7). To directly assess whether these
227 sequence differences affect assembly, we performed *in situ* cryo-ET and subtomogram
228 averaging of UOX assemblies from porcine and rat liver. Both porcine and rat UOX
229 assemblies closely recapitulated the structure in mice, exhibiting only minor differences
230 in helical parameters, while retaining identical fundamental repeating units and lateral
231 propagation rules (Figure 4b-g). These results indicate that the L81F and R82K—two
232 major differences between mice and other mammals—do not disrupt UOX assembly.
233 The previously reported morphological variability among these species may therefore
234 reflect limitations of two-dimensional projection imaging rather than fundamental
235 differences in three-dimensional assembly. Moreover, prior ultrastructural surveys of
236 hepatic peroxisomes²⁸ strongly suggest that UOX from additional mammals, including
237 bovine, sheep, rabbit, hamster, guinea pig, cat and dog, form similar assemblies. In
238 these species, the N148S variant is conserved and substitutions at positions 202 (R202K)
239 and 275 (I275V) preserve the physicochemical properties (Supplementary Figure 7).
240 Together, these observations suggest that the molecular principles governing UOX
241 assembly are conserved across most UOX-expressing mammals.

242

243 To evaluate conservation beyond mammals, we expanded our sequence analysis across

244 Chordata. Phylogenetic comparison revealed substantial divergence in assembly-
245 critical motifs outside mammals (Supplementary Figure 8a). Notably, several
246 substitutions alter key physicochemical properties of Interface A and C, including L81K
247 and I275S, which disrupt hydrophobic interactions, and N123D, which abolishes an
248 electrostatic contact (Supplementary Figure 8a-b). This divergence suggests that the
249 UOX assembly is not strictly preserved across broader Chordata lineages. This
250 conclusion aligns with earlier studies reporting UOX as a soluble protein in the
251 peroxisomal matrix of fish and amphibians, in contrast to the insoluble crystalloid forms
252 observed in more evolutionarily derived mammals⁴⁴⁻⁴⁶. Collectively, these findings
253 indicate that the UOX assembly represents a mammal-specific structural adaptation
254 rather than a universally conserved feature of uric acid metabolism.

255

256 **Function of the UOX assembly**

257 We next investigated the functional significance of UOX assembly formation. To assess
258 its physiological prevalence, we performed pelleting assays on mouse hepatic
259 peroxisome extracts, which revealed that over 90% of endogenous UOX partitions into
260 the assembly fraction (Supplementary Figure 5l-m). This observation indicates that the
261 assembly form represents the dominant intracellular state of UOX, which is probably a
262 functional state rather than an inactive storage pool. To evaluate whether assembly
263 formation modulates enzymatic activity, we compared the catalytic properties of the
264 UOX assembly isolated from liver extracts with that of purified homotetramers. The
265 UOX assembly retained robust catalytic activity, exhibiting only subtle differences to
266 tetramers (Figure 5a). Such minimal effects are inconsistent with canonical allosteric
267 regulation, in which high-order assembly typically accompanied by conformational
268 rearrangements that substantially alter enzyme activity^{21,47,48}.

269

270 Structural and computational analyses further support this conclusion. First, assembly
271 formation induces no major conformational changes: the root-mean-square deviation
272 (RMSD) of all residues between free UOX tetramers and those forming assembly
273 remained below 3.0 Å (Supplementary Figure 5k). Second, quantum

274 mechanics/molecular mechanics simulations revealed no significant structural
275 perturbations during catalysis, either globally or at interfacial residues. Over 100 ps
276 simulations, the RMSD for all atoms or C α atoms at the interfaces remained within 1.2–
277 1.6 Å, while the RMSD of all protein C α atoms stayed below 1.0 Å (Figure 5b,
278 Supplementary Figure 9a–g). These data together rule out allosteric regulation mediated
279 by assembly interfaces. Moreover, the catalytic sites remain accessible through
280 Interface B in the assembly state (Figure 5c), and the hollow fibers organize into a
281 porous lamellar architecture (Figure 3d). This configuration concentrates enzymes
282 while preserving extensive surface accessibility, thereby maintaining efficient substrate
283 entry and product diffusion. Collectively, these findings indicate that UOX assembly
284 function neither as stress-induced storage forms nor as allosteric regulators, but instead
285 represent a metabolically active state that sustains efficient urate turnover within
286 peroxisomes.

287

288 To directly test the functional relevance of this organization *in vivo*, we engineered a
289 UOX variant designed to selectively disrupt helix tiling assembly while preserving
290 tetrameric organization and catalytic function. Guided by structural comparison with
291 the non-assembling *Aspergillus flavus* homolog⁴⁹, we introduced steric hindrance at
292 Interface C by replacing residues 200-206 with the corresponding loop sequence in
293 *Aspergillus flavus* (Figure 5d, Supplementary Table 3). The resulting variant formed
294 stable tetramer and retained normal catalytic activity (Supplementary Figure 10a-c,
295 Supplementary Table 4). We then generated liver-specific *Uox* knockout mice and
296 rescued hepatic expression with either wild-type or mutant UOX at endogenous levels
297 (Supplementary Figure 10d-e). Electron microscopy confirmed the complete absence
298 of high-order UOX assemblies in the mutant peroxisomes, without detectable alteration
299 in overall peroxisomal morphology (Figure 5e-f, Supplementary Figure 10g-j). Despite
300 the loss of UOX assembly formation, mutant mice exhibited serum urate concentrations
301 indistinguishable from controls (Figure 5g). These findings demonstrate that UOX
302 assembly formation is dispensable for maintaining urate homeostasis under baseline
303 physiological conditions, suggesting that the tetrameric form alone is sufficient to

304 sustain catalytic flux *in vivo*.

305

306 We therefore considered whether the primary advantage of assembly lies not in
307 regulating catalysis but in enhancing molecular robustness through solid-state
308 organization. Indeed, compared with tetrameric UOX, the assembled state showed an
309 ~5 °C increase in melting temperature and markedly increased resistance to Proteinase
310 K digestion (Fig. 5h–i). To probe protection from oxidative damage in a peroxisome-
311 relevant context, we treated primary hepatocytes from rescue mice with 3-amino-1,2,4-
312 triazole (3-AT) to induce peroxisomal oxidative stress and quantified oxidative
313 modifications of UOX. UOX in the assembled state exhibited reduced oxidative
314 modification, as assessed by both free cysteine analysis and mass spectrometry (Fig.
315 5j–k). Because oxidative modifications can compromise activity and promote
316 degradation⁵⁰⁻⁵², these data support a functional model in which helix-tiling assembly
317 stabilizes UOX against chemical and proteolytic stress, enabling sustained catalysis in
318 the peroxide-rich peroxisomal matrix and contributing to long-term metabolic
319 robustness.

320

321 **Discussion**

322 Our *in situ* cryo-electron tomography (cryo-ET) analysis reveals a previously
323 unrecognized helix tiling assembly formed by urate oxidase (UOX) within mouse
324 hepatic peroxisomes. By resolving this architecture directly in native tissue at molecular
325 resolution, our study underscores the power of cryo-ET to uncover high-order
326 intracellular organizations that are not readily accessible by *in vitro* reconstitution or
327 conventional structural approaches. The detailed architecture of the UOX assembly
328 shows that the high-order organization is mediated by weak, multivalent interactions
329 between homotetramers involving several short structural motifs. This finding is
330 consistent with previous work demonstrating that subtle sequence features can
331 dramatically influence supramolecular assembly behavior⁵³⁻⁵⁵. Although no single
332 residue appears indispensable for assembly formation, the interactions are sufficiently
333 fragile that insertion of a short unstructured loop completely abolishes the high-order

334 organization. This sensitivity complicates evolutionary inference from sequence alone,
335 nevertheless, our comparative structural and phylogenetic analyses indicate that the
336 assembly is conserved among UOX-expressing mammals but not across Chordata,
337 suggesting that it may represent a lineage-specific evolutionarily advantageous
338 adaptation.

339

340 Molecular assemblies arising from molecular crowding—driven by weak, often
341 transient interactions—are pervasive in cells and frequently leads to phase separated
342 condensates or high-order solid-like states¹⁶. Metabolic enzymes are particularly prone
343 to such organization, and in many cases such assembly formation is coupled to allosteric
344 regulation of catalytic activity, enabling rapid metabolic control beyond transcriptional
345 regulation^{56,57}. While the UOX assembly we described can be reconstituted *in vitro*, it
346 forms only rarely under dilute conditions, indicating that the crowded peroxisomal
347 matrix plays an active role in promoting assembly formation beyond intrinsic sequence
348 determinants. Importantly, unlike many previously described enzyme assemblies, UOX
349 polymerization does not measurably alter catalytic activity, arguing against a regulatory
350 role and instead pointing to a distinct functional logic.

351

352 Structurally, the fivefold symmetry of UOX's hollow fiber architecture precludes space-
353 filling crystal packing, instead yielding a porous lamellar organization that maximizes
354 surface area while maintaining stability. This solid-state assembly is well suited to
355 preserve substrate accessibility and product diffusion while conferring substantial
356 protection against thermal, proteolytic, and oxidative stress. Such stabilization is likely
357 advantageous in the peroxisomal environment, which is enriched in hydrogen
358 peroxide—a reactive by-product of UOX catalysis. More broadly, our findings illustrate
359 how high-order enzyme organization can evolve to optimize molecular stability in harsh
360 intracellular environments without compromising catalytic efficiency, expanding
361 current paradigms of metabolic enzyme organization in crowded intracellular
362 environments.

363

364 UOX catalyzes urate oxidation to 5-hydroxyisourate, which *in vivo* is further processed
365 by HIU hydrolase and OHCU decarboxylase into S-(+)-allantoin^{58,59}. In certain
366 microorganisms, these enzymes assemble into multienzyme complexes⁶⁰, raising the
367 possibility that peroxisomal UOX assemblies may similarly coordinate downstream
368 partners. Although our subtomogram averages do not reveal stable, high-occupancy
369 association of these enzymes with the UOX assembly, transient or low-stoichiometry
370 interactions cannot be excluded and warrant further investigation.

371

372 UOX was lost during hominoid evolution, resulting in urate becoming the terminal
373 product of human purine catabolism—a change with important physiological and
374 pathological consequences, including susceptibility to hyperuricemia and gout. Current
375 treatments for hyperuricemia include urate synthesis inhibitors, uricosuric agents, and
376 uricolytic enzymes⁶¹. The later, such as recombinant *Aspergillus flavus* uricase
377 Rasburicase (ELITEKR)⁶² and the porcine–baboon chimeric enzyme Pegloticase
378 (KRYSTEXXA)⁶³, are effective but limited by their short plasma half-life and
379 immunogenicity⁶⁴. Although substantial effort has focused on engineering improved
380 UOX variants^{65,66}, our identification of a native higher-order UOX assembly suggests
381 that intrinsic self-association could influence therapeutic enzyme behavior *in vivo*. For
382 example, if administered UOX were to self-associate under physiological conditions,
383 this could alter effective particle size, diffusion and local microenvironment, with
384 potential consequences for stability, distribution and activity. These considerations
385 motivate strategies to control oligomeric state and formulation—such as tuning surface
386 interfaces or using encapsulation approaches⁶⁷⁻⁶⁹—to preserve stability while
387 minimizing unintended aggregation.

388

389 **Acknowledgments**

390 We thank Prof. Ning Gao, and Prof. Junyu Xiao for the critical suggestions. We are
391 grateful to the Cryo-EM Platform of Peking University and Changping Laboratory for
392 data collection, the High-Performance Computing Platform of Peking University for
393 assistance with computation, and the National Centre for Protein Sciences at Peking

394 University for technical assistance. We thank Dr. Ying-Chun Hu, Zhen-Yang Kong and
395 Meng-ting Xing for their technical assistance in EM sample preparation and image
396 analysis at the Core Facilities of School of Life Sciences, Peking University. This work
397 is funded by the National Key Research and Development Program of China
398 (#2024YFA1802800 to Q.G.), the National Natural Science Foundation of China
399 (#32371191 to Q.G.) and the Beijing Natural Science Foundation (JQ24031 to Q.G.).
400 Additional funds to Q.G. are provided by the Center for Life Sciences at Peking
401 University. Q.G. is supported by Changping Laboratory. The authors declare no
402 competing financial interests.

403

404 **Data availability**

405 The representative tomogram from mouse liver has been deposited in the Electron
406 Microscopy Data Bank (EMDB) under the accession code EMD-68842. The
407 subtomogram averaging maps have been deposited in the EMDB under the accession
408 codes EMD-68843 and EMD-68844 for mouse UOX assembly; EMD-68845 and
409 EMD-68846 for porcine UOX assembly; EMD-68847 and EMD-68848 for rat UOX
410 assembly. Cryo-EM coordinates and density maps have been deposited in the Protein
411 Data Bank (PDB) and EMDB under the accession codes PDB 23BS (EMD-68839) for
412 mouse UOX in the apo state; PDB 23BT (EMD-68840) for mouse UOX complexed
413 with UA; PDB 23BU (EMD-68841) for mouse UOX assembly isolated from liver.

414

415 **Author information**

416 These authors contributed equally: Junhan Yang, Zhe Chen, Yonglun Wang.

417

418 **Contributions**

419 Q.G. and X.C. conceived and designed the experiments. J.Y., W.D., Z.Y. and Y.Z.
420 prepared samples for the cryo-ET study. J.Y., W.D. and Z.Y. collected the cryo-ET data.
421 J.Y., W.D., Z.Y., Z.L. and S.L. processed the data and performed subtomogram
422 averaging. J.Y., Z.C. and Z.Y. prepared samples, collected and processed data for the
423 cryo-EM study. J.Y. and Z.C. built and refined the models. J.Y. and Z.C. designed and

424 performed the mutant protein assays. J.Y., Z.Y. and Z.C. performed enzyme activity
425 assays. S.Y. performed the MD analysis. X.S. and C.K. performed the sequence
426 alignment and phylogenetic analysis. Y.W. prepared the mice and primary hepatocytes,
427 performed serum uric acid and free cystines detection assays. X.S. performed the mass
428 spectrometry assays. J.Y., Z.C., Y.W., S.Y., X.S. and C.K. prepared the figures. J.Y.,
429 Z.C., Z.Y., Y.W., S.Y., X.S., C.K. and X.S. analyzed and interpreted the results. Q.G.
430 wrote the paper with the help of J.Y., Z.C., Y.W., S.Y., X.S. and C.K., and all authors
431 reviewed and revised it.

432

433 Corresponding authors:

434 Correspondence to Xiaowei Chen, Qiang Guo

435

436 **Ethics declarations**

437 Competing interests


438 The authors declare no competing interests.

439

440

441

442 **Figure legends**



443

444 **Figure 1: A supramolecular urate oxidase assembly in mouse hepatic peroxisomes**

445 **a**, 1.1 nm thick tomographic slice of a representative tomogram acquired from high-
 446 pressure-frozen mouse livers. The yellow arrowhead indicates a supramolecular UOX
 447 assembly within a peroxisome. Pero, peroxisome. Mito, mitochondrion. Scale bars, 100
 448 nm.

449 **b**, Three-dimensional rendering of the segmentation from the tomogram shown in (a).
 450 Yellow, mitochondrion. Magenta, ER membrane. Grey, ribosome. Green, peroxisome.
 451 Orange, the UOX assembly. Scale bars, 100 nm.

452 **c-d**, Representative top view (c) and corresponding schematic (d) of the UOX assembly.

453 Scale bars, 10 nm.

454 **e-f**, Representative side view (**e**) and corresponding schematic (**f**) of the UOX assembly.

455 Scale bars, 10 nm.

456 **g-h**, The schematic representation (**g**) and subtomogram averaging map (**h**) of the
457 fundamental repeating unit of the UOX assembly.

458 **i-j**, The schematic representation (**i**) and subtomogram averaging map (**j**) of a single
459 helical fiber within the UOX assembly.


460 **k**, Violin plot showing peroxisome diameter distribution measured from tomograms.

461 Data are presented as mean \pm SD.

462 **l**, Proportion of peroxisomes containing different numbers of UOX assemblies.

463 **m**, Single-particle cryo-EM density map (top) and atomic model (bottom) of mouse
464 urate oxidase.

465



466

467 **Figure 2: Inter-tetramer interactions governing UOX helical fiber**

468 **a**, Left, an individual helix from the UOX assembly. Middle and right, the side view
 469 and top view of the individual helix, with homotetrameric subunits labeled by index
 470 number; blue arrows showing the helix extension direction.

471 **b**, Two-dimensional schematic of the UOX helical fiber. Each homotetrameric subunit
 472 is assigned a unique index number. The yellow and purple colors represent the two
 473 strands of the double helix. Arrows indicate the direction of helix extension.

474 **c**, Localization of inter-subunit interfaces within the UOX helical fiber. Interface A,

475 Interface B and Interface C are highlighted by red, green and blue boxes, respectively.

476 **d**, Key residues involved in the formation of interface A.


477 **e**, Open-book view of the electrostatic surface potential at Interface C between UOX
478 homotetramers i and $i+2$. Blue and red indicate positive and negative charge,
479 respectively. Yellow circles mark specific interaction regions.

480 **f-g**, Key residues corresponding to regions marked in (e) that contribute to the
481 formation of interface C.

482 **h**, Open-book view of hydrophobic surface properties at Interface C between UOX
483 homotetramers i and $i+2$. Green indicates hydrophilic regions, and white indicates
484 hydrophobic regions. Yellow circle highlight interaction sites.

485 **i**, Key residues corresponding to regions marked in (h) that contribute to the formation
486 of interface C.

487



488

489 **Figure 3: Lateral propagation rules and lamellar architecture of the UOX helix**
490 **tiling assembly**

491 **a**, Schematic model of lateral extension of UOX helical fibers through sharing a column
492 of homotetramers via four interface C interactions. Green squares denote
493 homotetramers in the original fiber; yellow squares indicate newly incorporated
494 homotetramers. The helical axis and direction are indicated by dots and arrowed circles,
495 respectively.

496 **b**, (Top) Schematic illustrating permitted lateral extension involving three adjacent
497 fibers. (Bottom) Schematic of a sterically prohibited configuration resulting from
498 simultaneous extension into two immediately neighboring directions. Sterically clashed

499 subunits are highlighted with red boxes.

500 **c**, The “Three Breeds All” describing hierarchical lateral propagation of UOX fibers, in
501 which a three adjacent fibers unit serves as the repeating module for lamellar growth.


502 The number of fibers is indicated by level annotations.

503 **d**, Representative lateral extension pattern observed in a tomogram (left) and its
504 corresponding schematic (right). Scale bars, 10 nm.

505 **e**, Z-axis projection of the subtomogram averaging density map of a fundamental unit,
506 revealing a tree-like extension pattern. Yellow lines indicate potential extension paths.

507 **f**, Violin plot showing the distribution of extension levels per assembly. Data are
508 presented as mean \pm SD.

509



510

511 **Figure 4: Conservation of the UOX helix tiling assembly across mammals.**


512 **a**, Sequence conservation analysis of specific UOX motifs in Mammalia (n = 313),
 513 generated with WebLogo3⁷⁰. Residues directly involved in interactions are boxed in
 514 red (Interface A) or blue (Interface C), with those from mouse, rat and pig listed below.
 515 Numbers indicate corresponding residue positions in mouse UOX (UniProt ID:
 516 P25688).

517 **b**, 1.4 nm thick tomographic slice of a representative tomogram collected from high-
 518 pressure frozen porcine liver. Yellow arrowhead indicates UOX assembly. Pero,
 519 peroxisome. Mito, mitochondrion. Scale bars, 100 nm.

520 **c**, Three-dimensional rendering of the segmentation from the tomogram shown in (b).
 521 Yellow, mitochondrion. Magenta, ER membrane. Grey, ribosome. Green, peroxisome.
 522 Orange, the UOX assembly. Scale bars, 100 nm.

523 **d**, (Top) Subtomogram averaging density map of the fundamental unit of porcine UOX

524 assembly. (Bottom) Side view of a single UOX helical fiber within the assembly.
525 **e**, 1.2 nm thick tomographic slice of a representative tomogram collected from hepatic
526 peroxisomes isolated from rat liver. Yellow arrowhead indicates UOX assembly. Pero,
527 peroxisome. Scale bars, 100 nm.
528 **f**, Three-dimensional rendering of the segmentation from the tomogram shown in (**e**).
529 Green, peroxisome. Orange, the UOX assembly. Scale bars, 100 nm.
530 **g**, (Top) Subtomogram averaging density map of the fundamental unit of rat UOX
531 assembly. (Bottom) Side view of a single UOX helical fiber within the assembly.
532
533



534

535 **Figure 5: Functional consequences of UOX assembly formation.**

536 **a**, Relative enzyme activity of UOX tetramers and assembly. UOX abundance was
 537 assessed by western blot. Relative activity is normalized to the mean activity of the
 538 tetramer form. Data are presented as mean \pm SD; individual data points are shown.
 539 Statistical significance was assessed by Welch's unpaired *t*-test; $P < 0.05$ was considered
 540 significant.

541 **b**, Root-mean-square deviation (RMSD) plot of UOX in complex with substrate during
 542 the equilibration phase of the molecular dynamic simulation, with the UOX structure
 543 determined in this research used as the reference.

544 **c**, Structural details of interface B in the UOX assembly, showing that all active sites

545 remain accessible. Yellow circles indicate active sites; UOX homotetramers are labeled
546 by index number.

547 **d**, Structural basis for selective disruption of UOX assembly. The mutant UOX is fitted
548 to the assembly density map and aligned with wild-type UOX, revealing steric
549 hindrance introduced by replacement of residues 200–206 with the corresponding loop
550 sequence from *Aspergillus flavus* at interface C. (Top) The substituted loop is
551 highlighted. (Bottom) Predicted steric clashes are marked with red dotted lines.

552 **e**, Representative transmission electron micrograph of liver from wild-type UOX rescue
553 mice. Yellow arrowheads indicate peroxisomes containing typical UOX assembly.
554 Scale bars, 200 nm.

555 **f**, Representative transmission electron micrograph of liver from mutant UOX rescue
556 mice. Yellow arrowheads indicate peroxisomes lacking UOX assembly. Scale bars, 200
557 nm.

558 **g**, Serum uric acid level of wild-type, *Uox* liver specific knockout (LKO), WT UOX
559 rescue and mutant UOX rescue mice. The data are presented as the mean \pm SD, with
560 each data point reflecting one mouse. Statistical significance was analyzed using
561 unpaired *t*-test, with $P < 0.05$ considered statistically significant.

562 **h**, Thermostability of UOX tetramers and assembly, assessed by residual activity after
563 incubation at indicated temperatures. The temperatures at which the enzymes retained
564 half of their activity (T_m) were determined in GraphPad Prism 9. The data are presented
565 as the mean \pm SD.

566 **i**, Proteinase K resistance of UOX tetramers and assembly, plotted as residual activity
567 after digestion for the indicated times. The data are presented as the mean \pm SD.

568 **j**, Functional cysteine levels of UOX (WT and assembly-disrupting mutant) purified
569 from primary hepatocytes, which were isolated from rescue mouse livers and cultured
570 with 10 mM 3-AT. UOX protein levels were quantified by Coomassie Blue staining.

571 **k**, Mass spectrometry analysis of oxidative modifications on UOX purified from
572 primary hepatocytes isolated from mouse livers and cultured in presence of 10 mM 3-
573 AT. Red indicates residues exhibiting higher levels of oxidative modification in the
574 assembly-disrupting mutant relative to wild-type UOX, whereas blue indicates lower

575 modification levels.

576

577 **Methods**

578 **High-pressure freezing**

579 The mouse liver samples were vitrified using a previous established protocol^{14,71} with
580 some modifications. In brief, the abdomen of each mouse was dissected under
581 anesthesia. A small piece of liver tissue was meticulously excised using a scalpel and
582 immersed in phosphate-buffered saline (PBS) supplemented with 20% (w/v) dextran
583 and 5% (w/v) sucrose for 30 s before being placed onto an EM grid (copper, 200 mesh,
584 Beijing XXBR., Catalogue no. T10012). The grid was coated with an additional carbon
585 layer (~20 nm thick) and freshly glow discharged using a Model 950 Advanced Plasma
586 System (Gatan, Pleasanton, CA, USA) before usage. The grid was previously placed
587 into a 6 mm aluminum carrier (200 nm in depth). After filling the carrier with 2-
588 methylpentane (Sigma), a 6 mm sapphire disc was immediately placed on top of the
589 carrier. The assembly of the sandwich carrier was promptly inserted into the high-
590 pressure cryostat (Leica EM ICE) for vitrification. The vitrified sandwich assembly was
591 then transferred to a liquid ethane and propane mixture (ethane:propane=36.9%:63.1%)
592 at -170°C, allowing 2-methylpentane to dissolve. The resulting grid was then
593 transferred to liquid nitrogen for storage until milling.

594

595 For porcine liver samples, fresh livers were obtained from a local market and processed
596 immediately. Tissue samples were separated using a sterile biopsy punch and immersed
597 in phosphate-buffered saline (PBS) supplemented with 20% (w/v) dextran and 5% (w/v)
598 sucrose for 30 s. Samples were then transferred onto an EM grid same as above.
599 Subsequent procedures were performed under identical parameters as described for
600 mouse liver tissues.

601

602 **The cryo-lift-out and lamella thinning**

603 A cryo-FIB (Aquilos 2, Thermo Fisher Scientific) was employed to prepare lamellae,
604 using an adapted serial lift-out method^{71,72}. Briefly, the grid was clipped into an
605 Autogrid (ThermoFisher Scientific) before being loaded onto the FIB chamber via the
606 sample transfer rod. To minimize the ion beam damage and enhance the electrical

607 conductivity, the sample was coated with a layer of platinum (Pt) using gas injection
608 system (GIS) for 2 min, followed by sputtering at 30 mA for 15 s. Initially, a copper
609 block (~10×15 μm) is milled from the half-grid (copper, Beijing XXBR., Catalogue no.
610 T1109M-3) at room temperature and attached to the Easylift needle by redeposition
611 (beam current: 1 nA). Next, four trenches were milled around the region of interest with
612 the ion beam (beam current: 3 nA) to expose the sample block. This block was
613 subsequently attached to the copper block by redeposition (beam current: 0.5 nA) and
614 transferred to the receiver grid (copper, 100/400 mesh, Beijing XXBR., Catalogue no.
615 G100/400), where it was serially sectioned to several lamellae with a thickness of ~3
616 μm. These lamellae were securely attached to the grid in turn by two-sided redeposition
617 method (beam current: 0.5 nA). Finally, each lamella was finely milled (beam current
618 from 1 nA to 30 pA) to a target thickness of approximal 200 nm, which was then used
619 for subsequent tomographic data acquisition.

620

621 **Cryo-ET Data Acquisition**

622 For lamellae from mouse livers, they were loaded to a 300 kV cryo-transmission
623 electron microscope Titan Krios G3 (ThermoFisher Scientific) equipped with a K3
624 camera and a Gatan energy filter. Automatic tomographic tilt series acquisition was
625 performed using SerialEM software⁷³ with the Plugin PACE-tomo⁷⁴. Images were
626 acquired at a magnification of 64000× (pixel size was 1.37 Å) in TIFF format using
627 super-resolution mode, resulting in 10 frames per image. The defocus was set from -4.0
628 to -6.0 μm. The acquisition was performed from -50° to +50° (with respect to the pre-
629 tilt angle) in 2° increments, utilizing the dose symmetric scheme^{75,76}. The dose rate was
630 set to 13 e/pixel/s and total dose was limited to 120 e/Å² per tilt series.

631

632 For lamellae from porcine livers, they were loaded to a 300 kV cryo-transmission
633 electron microscope Titan Krios G4 (ThermoFisher Scientific) with a Falcon 4 camera
634 and a ThermoFisher Selectris X energy filter. Automatic tomographic tilt series
635 acquisition was performed using Tomography 5.12.0 (ThermoFisher Scientific).
636 Images were acquired at a magnification of 53000× (pixel size was 2.37 Å) in EER

637 format. The defocus was set from -4.0 to -6.0 μm . The acquisition was performed from
638 -44° to $+44^\circ$ (with respect to the pre-tilt angle) in 2° increments, utilizing the dose
639 symmetric scheme. The dose rate was set to 9.74 e/pixel/s and total electron dose per
640 tilt series was limited to 120 e/ \AA^2 .

641

642 For isolated peroxisomes from rat livers, they were loaded to a 300 kV cryo-
643 transmission electron microscope Titan Krios G4 (ThermoFisher Scientific) with a
644 Falcon 4 camera and a ThermoFisher Selectris X energy filter. Automatic tomographic
645 tilt series acquisition was performed using Tomography 5.12.0 (ThermoFisher
646 Scientific). Images were acquired at a magnification of 64000 \times (pixel size was 1.94 \AA)
647 in EER format. The defocus was set from -3.0 to -5.0 μm . The acquisition was
648 performed from -50° to $+50^\circ$ in 2° increments, utilizing the dose symmetric scheme.
649 The dose rate was set to 7.87 e/pixel/s and total electron dose per tilt series was limited
650 to 120 e/ \AA^2 .

651

652 **Tomogram reconstruction and denoising**

653 TOMOMAN⁷⁷ and TOM toolbox⁷⁸ were used as general tools in image processing.
654 Initially, for TIFF format files, all frames of each tilt were motion corrected using
655 MotionCor2 software⁷⁹. While for EER format files, the frames with a dose of
656 approximal 0.10 e/ \AA^2 were fractioned (depend on the specific EER frames) before
657 motion correction by MotionCor2 software. After cleaning bad tilts and dose filtering⁸⁰,
658 each tilt series was aligned using patch-tracking method either in AreTomo2 software⁸¹
659 or in IMOD software⁸², followed by reconstructing using back projection method to
660 obtain a tomogram. All tomograms were rescaled before further processing.
661 Specifically, the tomograms from mouse livers were binned by a factor of 8, while
662 tomograms from porcine livers and rat peroxisomes used a binning factor of 6
663 depending on the specific pixel size. For visualization, tomograms were denoised either
664 with cryoCARE⁸³ or IsoNet⁸⁴ before a deconvolution filter were applied to further
665 improve the contrast⁸⁵.

666

667 **Subtomogram averaging**

668 Subtomogram averaging was performed using an integrated workflow involving
669 software: IMOD⁸², Warp⁸⁵, RELION⁸⁶, M⁸⁷, and ChimeraX⁸⁸.

670

671 Mouse UOX assembly were manually traced as fibers in IMOD, with at least three
672 points per fiber marked to define their trajectories. Coordinates were saved in .mod
673 format and converted to text files using the “model2point” command in IMOD. Custom
674 scripts were used to split these text files into individual fiber-specific coordinate lists.
675 Fiber coordinates were oversampled at 70 Å intervals using the “relion_helix_toolbox”
676 command, generating 25,040 points in total. Subtomograms (binning factor 4, box size
677 526 Å) were extracted based on these coordinates. Initial alignment was performed in
678 RELION/2.1⁸⁹ via 3D auto-refinement, using the additional arguments “sigma_tilt=15”
679 and “sigma_psi=15”. The initial reference map was directly 3D-reconstructed from the
680 subtomograms. Following alignment, the one representative fiber was re-centered
681 within the box and re-extracted. Another 3D auto-refinement in RELION/3.1⁹⁰ yielded
682 an average map with three adjacent fibers. Manual adjustment of particle coordinates
683 and Euler angles was performed in ChimeraX using the ArtiaX plugin⁹¹. For
684 subtomograms derived from the same fiber, the coordinates should distribute evenly
685 (the distance = refined inter-segment distance) along the fiber axis; the Euler angle
686 orientations were the same and determined by the relative spatial positioning of two
687 adjacent fibers. The badly aligned particles were removed during manual adjustment.
688 Subtomograms were then re-extracted at the binning factor of 2 and locally refined with
689 tighter constraints on Euler angles before applying helical symmetry (rise=14.69 Å,
690 twist=-143.82°). The parameters were measured manually from the density map and
691 optimized using the “relion_helix_toolbox” command within a certain range. After
692 confirming helical symmetry, subtomograms were re-extracted at the binning factor of
693 2, retaining only the first 25 low-dose tilts from each tomogram to improve resolution.
694 Another round of 3D auto-refinement with helical symmetry and masking in
695 RELION/3.1 was conducted, followed by further optimization in M software through
696 improving tomogram alignment. The final refinement was processed in RELION/3.1

697 with helical symmetry and masking⁹², yielding a map at 7.3 Å resolution (final refined
698 helical parameters: rise=14.53 Å, twist=-144.11°) with 17,221 subtomograms from 22
699 tomograms. The local resolution was estimated using Relion.

700

701 For subtomogram averaging of ribosomes, initial ribosome positions and orientations
702 were determined by template matching using PyTOM⁹³ on five 8× binned tomograms,
703 followed by manually screening. The results were fed to DeepFinder⁹⁴ to train a neural
704 network for picking ribosomes on all remaining 8× binned tomograms, obtaining
705 ~12,000 particles. After extracting subtomograms at 5.48 Å/px (4× binning) in Warp,
706 they were subjected to iterative rounds of alignment and classification in RELION/3.1.
707 The best class of ribosomes were 3D auto-refined before re-extracting at 2.74 Å/px (2×
708 binning), followed by local 3D auto-refinement. The result was imported to M for
709 improving alignment of tomograms before re-extracting at 2.055 Å/px (1.5× binning),
710 followed by one more local 3D auto-refinement in RELION/3.1 and yielding a map at
711 9.6 Å resolution with 8,350 particles.

712

713 **Membrane Segmentation and tomographic back-plotting**

714 Tomograms were denoised and missing-wedge corrected by IsoNet prior to membrane
715 segmentation, which was firstly performed using MemBrain-Seg⁹⁵ with the pre-trained
716 model and then manually polished with Amira 3D 2022.2 (Thermo Fisher Scientific).
717 Ribosomes and UOX assembly are the back-plotting of STA maps at coordinates after
718 3D refinement. A gaussian filter was applied to membranes and particles in ChimeraX
719 for the final rendering.

720

721 **Measurement of peroxisome size**

722 The size of peroxisomes was estimated from tomograms. For each peroxisome, its size
723 was determined by measuring the long-axis diameter of its largest cross-sectional slice
724 within the tomogram.

725

726 **Molecular cloning and mutagenesis**

727 The mouse urate oxidase gene (*mUox*, UniProt ID: P25688) was codon-optimized,
728 synthesized and cloned into the pET-28a expression vector. The UOX bear an His-
729 SUMO fusion tag at its N-terminal to facilitate the purification. Site-directed
730 mutagenesis targeting the loop region spanning amino acid residues 200-206 was
731 performed using Phanta Max Super-Fidelity DNA polymerase (Vazyme Biotech Co.,
732 Ltd), with mutated sequence on the primers. This mutagenesis enabled the replacement
733 of the loop sequence with its homologous sequence from *Aspergillus flavus*. The
734 resultant UOX mutant was validated through DNA sequencing prior to use.

735

736 **Protein expression and purification**

737 For the purification of His-SUMO-UOX (WT) and His-SUMO-UOX (mutant), the
738 plasmids were transformed into BL21 (DE3) *E. coli* for protein expression. The
739 transformed cells were grown at 37°C to OD₆₀₀ 0.6–0.8. The culture was then cooled to
740 18°C and protein expression was induced by the addition of 0.5 mM IPTG for 18 h.
741 Cells were harvested by centrifugation, the pellet was resuspended in lysis buffer (20
742 mM Tris, 150 mM NaCl, pH 8.0) before sonication and centrifugation. The supernatant
743 was loaded onto a Ni-NTA agarose column for three times, washed with lysis buffer
744 supplemented with 100 mM imidazole, and eluted with lysis buffer supplemented with
745 300 mM imidazole. The eluted fractions were concentrated to 1 mL before being loaded
746 on a Superdex 200 Increase 10/300 GL (GE healthcare) column equilibrated with buffer
747 B (100 mM NaHCO₃-Na₂CO₃, pH 10.4). The purity was confirmed by SDS-PAGE, and
748 the protein was concentrated to at least 10 mg/mL for the replacement with lysis buffer
749 before plunge freezing and stock at -80°C.

750

751 **Isolation of peroxisomes from murine livers**

752 The procedure for peroxisome isolation from murine livers was similar to the
753 previously established protocol^{96,97} by Andreas Manner et al. with some modifications.
754 Briefly, following overnight starvation, approximately 10 g of murine liver tissue was
755 excised. Tissues were rinsed three times with ice-cold phosphate-buffered saline (PBS)
756 and homogenized in ice-cold HB buffer (250 mM sucrose, 5 mM MOPS, 1 mM EDTA,

757 2 mM PMSF, 1 mM DTT, pH 7.4) using three homogenization cycles at 500 rpm on
758 ice. The homogenate was centrifuged at 600 g for 10 min at 4°C to pellet debris, and
759 the supernatant was retained. The pellet was re-homogenized under identical conditions
760 and re-centrifuged; supernatants from both cycles were pooled. The combined
761 supernatant was subjected to sequential centrifugation steps: first at 2,700 g for 10 min
762 at 4°C, followed by re-suspension and re-centrifugation of the pellet under identical
763 conditions. The pooled supernatants were further centrifuged at 37,000 g for 20 min.
764 After discarding the supernatant and reddish layer on top of the pellet, the remaining
765 pellet was gently re-suspended in a minimal volume of HB buffer (<5 mL) and
766 maintained on ice as the light mitochondrial (LM) fraction.

767

768 OptiPrep density gradients (1.12, 1.15, 1.19, 1.22, and 1.26 g/mL) were prepared by
769 diluting 60% OptiPrep stock solution (1.32 g/mL; Sigma-Aldrich) with GB buffer (5
770 mM MOPS, 1 mM EDTA, 2 mM PMSF, 1 mM DTT, pH 7.4). Using 13.2 mL
771 ultracentrifuge tubes (Beckman Coulter Inc.), gradients were layered sequentially in
772 decreasing density order (1.26–1.12 g/mL) with volumes of 1, 0.75, 1.5, 1.75, and 2.5
773 mL, respectively. Subsequently, 5 mL of the light mitochondrial fraction was layered
774 on top of the gradient. Centrifugation was performed using an SW 41 Ti rotor (Beckman
775 Coulter) at 33,000 *g*_{max} for 53 min. Following centrifugation, peroxisomes were
776 predominantly localized in the lower three bands, which were carefully aspirated. The
777 collected fractions were diluted 1:4 (v/v) with HB buffer and pelleted by centrifugation
778 at 37,000 g for 15 min. The final pellet was re-suspended in a minimal volume (100–
779 200 µL) of lysis buffer (20 mM Tris, 150 mM NaCl, pH 8.0) or HB buffer supplemented
780 with 0.25% Triton X-100 (v/v) for single-particle analysis (SPA) sample preparation
781 and biochemical assays.

782

783 **Single-particle Cryo-EM sample preparation**

784 For purified UOX protein samples without its substrate UA, the cryo-EM holey carbon
785 grids (Quantifoil, R2/1, Au, 200 mesh) were glow-discharged before plunge freezing
786 using an FEI Vitrobot IV with 100% humidity and 4°C. Around 4 µL aliquots of the

787 prepared protein samples (~1 mg/mL) were applied to the grids, and blotted with a force
788 of 0 and time of 3 s before plunge freezing in liquid ethane.

789

790 For purified UOX protein samples with its substrate UA, the cryo-EM holey carbon
791 grids (Quantifoil, R1.2/1.3, Cu, 200 mesh) were glow-discharged before plunge
792 freezing using an FEI Vitrobot IV with 100% humidity and 4°C. Protein samples were
793 concentrated to approximately 1 mg/mL in lysis buffer (20 mM Tris, 150 mM NaCl,
794 pH 8.0) saturated with UA. To ensure saturation was maintained, additional UA was
795 supplemented prior to sample preparation. Around 4 μ L aliquots were applied to the
796 grids, and blotted with a force of 0 and time of 3 s before plunge freezing in liquid
797 ethane.

798

799 For isolated peroxisomes from mouse livers, the cryo-EM holey carbon grids
800 (Quantifoil, R2/1, Cu, 200 mesh) were glow-discharged before plunge freezing using
801 an FEI Vitrobot IV with 50% humidity and 4°C. Around 4 μ L aliquots of the peroxisome
802 samples were applied to the grids, and blotted with a force of 0 and time of 5 s before
803 plunge freezing in liquid ethane.

804

805 **Single-particle Cryo-EM data acquisition**

806 For purified UOX protein samples without its substrate UA, the cryo-EM data was
807 acquired in the 300 kV Titan Krios G4 microscope equipped with a Selectris X energy
808 filter using the EPU software (Thermo), with a nominal magnification of 165,000 \times
809 (pixel size: 0.74 Å) and a defocus range of -1.0 to -1.4 μ m. The images were recorded
810 using a Thermo Falcon 4 camera with counted mode in EER format, with a dose rate
811 of 15.41 e⁻/s/Å², a total dose of 60 e⁻/Å², a total exposure time of 3.90 s, and a total
812 frame of 938.

813

814 For purified UOX protein samples with its substrate UA, the cryo-EM data was
815 acquired in the 300 kV Titan Krios G4 microscope equipped with a Selectris X energy
816 filter using the EPU software (Thermo), with a nominal magnification of 165,000 \times

817 (pixel size: 0.74 Å) and a defocus range of -1.0 to -1.4 μm. The images were recorded
818 using a Thermo Falcon 4 camera with counted mode in EER format, with a dose rate
819 of 17.71 e⁻/s/Å², a total dose of 60 e⁻/Å², a total exposure time of 3.38 s, and a total
820 frame of 812.

821

822 For isolated peroxisomes from mouse livers, the cryo-EM data was acquired in the 200
823 kV Glacios2 microscope equipped with a Selectris X energy filter using the EPU
824 software (Thermo), with a nominal magnification of 130,000× (pixel size: 0.93 Å) and
825 a defocus range of -1.0 to -2.0 μm. The images were recorded using a Thermo Falcon
826 4 camera with counted mode in EER format, with a dose rate of 11.09 e⁻/s/Å², a total
827 dose of 60 e⁻/Å², a total exposure time of 5.41 s, and a total frame of 1302.

828

829 **Single-particle Cryo-EM image processing**

830 For purified UOX without UA, images were processed in RELION/4.0⁹⁸. A total of
831 19,264 dose-fractionated movies were motion-corrected using RELION's
832 implementation of MotionCor2, followed by CTF estimation with CTFFIND4⁹⁹. After
833 selection, 14,858 micrographs were retained for further processing. Particles were
834 template-picked using a 3D reference (PDB: 4MB8) and curated via several rounds of
835 2D classification. Selected particles underwent 3D classification with D2 symmetry.
836 The best class, containing 101,075 particles, was subjected to 3D auto-refinement, CTF
837 refinement, and Bayesian polishing¹⁰⁰. The final map reached a resolution of 2.79 Å
838 based on the gold-standard FSC = 0.143 criterion¹⁰¹. Map quality was further improved
839 using DeepEMhancer¹⁰², and local resolution was estimated in RELION. Directional
840 FSC and sphericity were calculated using 3DFSC¹⁰³.

841

842 For purified UOX with UA, images were processed in cryoSPARC version 4.6.0¹⁰⁴. A
843 total of 22,739 movies were aligned via patch motion correction, and CTF parameters
844 were estimated using patch CTF. Following curation, 13,402 micrographs were selected.
845 Particles were picked using both template matching and Topaz¹⁰⁵, then cleaned via
846 reference-free 2D classification. Selected particles underwent heterogeneous

847 refinement using an ab initio reconstruction as the initial model. The best class was
848 iteratively optimized through non-uniform refinement¹⁰⁶, orientation rebalancing and
849 heterogeneous refinement. The final reconstruction, comprising 304,325 particles,
850 reached a resolution of 2.42 Å (FSC = 0.143). The map was post-processed with
851 DeepEMhancer. Local resolution and anisotropy were assessed using cryoSPARC and
852 Orientation Diagnostics, respectively.

853

854 For isolated peroxisome samples, images were processed in cryoSPARC version 4.6.0
855 and RELION/5.0. A total of 3,929 movies were aligned via patch motion correction,
856 and CTF parameters were estimated using patch CTF in cryoSPARC. A subset of 888
857 micrographs containing distinct UOX fibers was manually selected and imported into
858 RELION 5.0. Fibers were manually picked by defining start-end coordinates and
859 extracted with an inter-box distance of 70 Å and a box size of 428 Å. Following three
860 rounds of 2D classification (binned by 2), a subset of particles was subjected to 3D
861 auto-refinement to optimize helical parameters (twist = -144.095°, rise = 15.52 Å).
862 Particles were then imported back into cryoSPARC and re-extracted without binning.
863 Non-uniform refinement was performed using a subtomogram averaging map as the
864 initial reference, followed by helical refinement. After CTF refinement and reference-
865 based motion correction, helical refinement was applied with D1 symmetry, and
866 duplicates were removed based on a minimum distance of 30 Å. Finally, symmetry
867 expansion was performed using the final helical parameters (twist = -144.11°, rise =
868 15.52 Å), followed by local refinement masked to the central 40% of the fiber. This
869 yielded a final map at 3.64 Å resolution comprising 219,322 particles. Map quality was
870 improved using EMReady¹⁰⁷, and local resolution was estimated using in cryoSPARC.

871

872 **Model building and refinement**

873 Atomic models were initially generated using model-angelo¹⁰⁸ or cryoNet¹⁰⁹ based on
874 maps post-processed using DeepEMhancer or EMReady. These models were manually
875 adjusted with Coot¹¹⁰. The model of the UOX-UA complex was derived from the apo-
876 UOX structure, while the UOX fiber model was built upon the UA-complexed UOX

877 structure. All final models were refined using phenix.real_space_refine^{111,112} with
878 geometric constraints and validated using MolProbity¹¹³. Figures of cryo-EM density
879 maps and analyses of molecular interactions were prepared using ChimeraX, Chimera
880 ¹¹⁴ and PyMOL ¹¹⁵.

881

882 **Western blotting**

883 For detection of UOX during peroxisome isolation, 10 μ L of aliquots from each
884 centrifugation stage and Optiprep gradient fraction were loaded for SDS-PAGE (10%
885 w/v) analysis and transferred to PVDF membranes. Membranes were blocked and
886 incubated with primary antibodies (uricase 1:500; sc-166214, Santa Cruz
887 Biotechnology) followed by incubation with an HRP-conjugated goat anti-mouse IgG
888 secondary antibody (1:25,000, HA1006, HUABIO). Chemiluminescent signals were
889 captured using a Tanon-5200 Imaging System.

890

891 For determination of UOX abundance in activity assays, total protein concentrations of
892 purified UOX and lysed peroxisomes were determined using BCA protein assay kit
893 (Thermo Fisher Scientific). For each sample, approximately 0.5 μ g of total protein was
894 loaded in triplicate onto SDS-PAGE gels for immunoblotting, as described above. Band
895 intensities were quantified via integrated density analysis using ImageJ (NIH). These
896 values were subsequently used to normalize the specific activity of UOX across
897 samples. Data analysis and visualization were performed using GraphPad Prism (v9.0),
898 with results expressed as mean \pm SD from three technical replicates. All experiments
899 were independently repeated three times to ensure biological reproducibility.

900

901 For pelleting assay of UOX in peroxisomes, lysed peroxisomes were centrifuged at
902 25,000 \times g for 15 min at 4°C. The resulting supernatant and pellet fractions were
903 separated, with the pellet resuspended in a volume of HB buffer equivalent to the
904 supernatant. Equal volumes of the total peroxisome lysate, supernatant, and pellet
905 fractions were analyzed by western blotting under identical conditions. Band intensities
906 were quantified via integrated density analysis using ImageJ (NIH), and data were

907 normalized to the mean density of peroxisome samples. Graphs were generated in
908 GraphPad Prism (v9.0). Means and error bars represent the average and standard
909 deviation (SD) of triplicate lane measurements, respectively. Ratios of normalized
910 values were calculated using error propagation formulas to determine mean and SD.
911 All experiments were independently repeated three times to ensure biological
912 reproducibility.

913

914 **UOX activity assay**

915 The UOX enzymatic activity was determined spectrophotometrically by monitoring the
916 decrease of uric acid by following the absorbance at 293 nm (A₂₉₃). A freshly prepared
917 1 mM uric acid stock in lysis buffer (20 mM Tris, 150 mM NaCl, pH 8.0), was diluted
918 with lysis buffer to prepare a uric acid concentration of 300 μM. The concentration of
919 all UOX samples was determined by the BCA protein assay kit (Thermo Fisher
920 Scientific). For each assay, 200 μL of uric acid solution was dispensed into individual
921 wells of a 96-well plate and pre-incubated at 37°C. Prior to initiating the reaction, 10
922 μL of enzyme solution (total protein concentration: 0.1 mg/mL) or buffer alone was
923 added to each well. Absorbance changes at 293 nm were recorded every minute for 20
924 min at 37°C using a microplate reader. The specific activity for all UOX samples was
925 defined as the amount of uric acid substrate (in μM) oxidized per minute per milligram
926 of total protein.

927

928 **Determination of kinetic parameters**

929 A freshly prepared 1 mM uric acid stock in lysis buffer (20 mM Tris, 150 mM NaCl,
930 pH 8.0), was diluted with lysis buffer to prepare a range of uric acid concentrations.
931 Specifically, the assays were performed at the following uric acid concentrations: 10
932 μM, 20 μM, 30 μM, 50 μM, 75 μM, 100 μM, 150 μM, and 200 μM. Each experiment
933 included triplicate technical replicates, and three independent biological replicates were
934 performed. The average initial reaction rates from triplicate samples were used to fit
935 the Michaelis-Menten equation and calculate V_{max} and K_m values in GraphPad Prism
936 v9.0. The concentration of all UOX samples was determined by the BCA protein assay

937 kit (Thermo Fisher Scientific). Catalytic efficiency (k_{cat}) was derived by dividing V_{max}
938 by the total enzyme concentration. The data are presented as the mean \pm standard
939 deviation (SD) of at least three independent experiments.

940

941 **Thermostability analysis**

942 The purified UOX and isolated, lysed peroxisomes were quantified using the BCA
943 protein assay kit (Thermo Fisher Scientific) to get a concentration of 0.1 mg/mL before
944 incubating for 3 min at various temperatures (40,45,50,55,60,65,70,80,90°C). Then
945 they were transferred on ice for at least 10 min before the residual enzymatic activity
946 was assayed using the method described above. The activity was measured in triplicate
947 technical replicates for each sample and was normalized to the untreated control (0°C
948 heat treatment) to account for baseline variations. The decline in enzymatic activity as
949 a function of temperature was fitted using nonlinear regression with a sigmoidal dose-
950 response model in GraphPad Prism v9.0. The melting temperature (T_m) for each
951 sample was defined as the temperature at which 50% of enzymatic activity was lost
952 relative to the untreated control.

953

954 **Proteinase K resistance assay**

955 Proteinase K resistance assay was performed with the following reaction system: 90 μ L
956 sample (purified protein or isolated peroxisomes) was incubated with 9 μ L Proteinase
957 K solution (containing 9 μ g sample proteins and 2.25 μ g Proteinase K) at 37°C with
958 shaking at 200 rpm. Reactions were terminated at time points of 0.5, 1, 1.5, and 2 h by
959 adding phenylmethylsulfonyl fluoride (PMSF) to a final concentration of 1 mM.
960 Untreated samples supplemented with 9 μ L lysis buffer (20 mM Tris, 150 mM NaCl,
961 pH 8.0) served as controls. Residual enzymatic activity was measured for all samples
962 under identical parameters as described for the UOX activity assay, with at least three
963 technical replicates per time point.

964

965 **UOX mutant structure prediction**

966 The UOX mutant used in this paper was created by replacing the loop corresponding to

967 amino acids 200-206 with the one from *Aspergillus flavus* homolog. The full-length
968 sequence of mutant UOX was used to predict its structure using AlphaFold3¹¹⁶.

969

970 **Quantification and statistical analysis**

971 The activity curves were generated by averaging triplicate measurements, with error
972 bars representing \pm standard deviation (SD). All fitting parameters, including kinetic
973 parameters and T_m values, were derived from at least three independent biological
974 replicates to ensure reproducibility. Statistical comparisons between purified UOX
975 tetramers and UOX assembly from peroxisome samples were performed using Welch's
976 unpaired *t*-tests obtained from technical triplicates across biological replicates.

977

978 **Animals**

979 All animal housing and use procedures were approved by the Institutional Animal Care
980 and Use Committees of Peking University, an AAALAC accredited laboratory animal
981 facility. All mice used in the experiments were provided by Peking University and bred
982 on the C57BL/6J background. All rats used in the experiments were Wistar IGS
983 background purchased from Vital River Laboratory Animal Technology Co., Ltd. *Uox*
984 liver knockout (KO) mice were obtained by intravenous injecting spCas9 mice with
985 AAV 2/8 carrying TBG-Cre and *Uox* targeting sgRNA. Cre-dependent spCas9 knockin
986 (KI) mice were purchased from the Jackson Lab (RRID: IMSR_JAX: 026556). Mice
987 were housed under standardized conditions, including a temperature of approximately
988 22°C, a 12 h light/dark cycle, and humidity of 40%-60%. Mice had free access to food
989 and water unless otherwise stated. Mice aged 6 weeks were used in all experiments.
990 Mice were randomly assigned to different experimental groups.

991

992 **DNA vector construction**

993 For CRISPR/Cas9-mediated acute knockout of UOX in mouse liver, pX602-AAV-Cre-
994 sgRNA plasmid was edited from pX602 (Addgene, 61593) vector according to
995 previously reported procedures¹¹⁷. In brief, sequence of Cre recombinase was inserted
996 after the TBG promoter region, with the sequence of human U6 promoter and spCas9

997 sgRNA-scaffold cloned into the same vector. The sgRNA sequence was designed by
998 the Benchling website. sgRNA 5'-tgtcgggaattatcacccgtgt-3' was used for *Uox* gene
999 knockout in mouse liver. For UOX (WT/mutant) rescue in mouse liver, the cDNA
1000 sequence of FLAG-UOX (WT/mutant) were inserted into AAV-TBG-cDNA vector
1001 which was generated from AAV-TBG-GFP (Addgene, 105535). To avoid sgRNA-
1002 guided editing in UOX expression plasmids, the PAM region of sgRNA was mutated in
1003 an amino acid synonymous mutation form.

1004

1005 **Adeno-Associated Virus (AAV) production and delivery**

1006 HEK293T cells were used for AAV packaging. In brief, Rep/Cap (2/8) plasmids, delta-
1007 F6 plasmids and AAV shuttle vector plasmids were transfected into 293T cells by using
1008 PEI according to the manufacturer's instructions. Cells were scraped from culture
1009 dishes at 48 h after transfection. Viruses were purified by using Optiprep density
1010 gradient ultracentrifugation and quantified by qPCR of virus genome as previous
1011 reported¹¹⁷. For AAV delivery, tail vein injection was used into 6-week-old C57BL/6J
1012 mice. 4E11 viral genome copies of pX602-AAV-Cre-sgRNA were used for UOX
1013 knockout. For rescue experiments, 1E11 viral genome copies of AAV-TBG-FLAG-
1014 UOX (WT/mutant) were used together with 4E11 sgRNA virus.

1015

1016 **Serum uric acid detection**

1017 Blood samples were collected from wild-type mice, UOX liver-specific knockout (LKO)
1018 mice, and UOX (WT / mutant) rescue mice under ad libitum feeding conditions. Plasma
1019 was obtained by centrifuging the blood at 6,000 rpm for 5 min at 4°C, and the resulting
1020 supernatant (serum) was separated. Serum uric acid levels were measured using Uric
1021 Acid (UA) Colorimetric Assay Kit (E-BC-K016-M).

1022

1023 **Primary hepatocyte isolation**

1024 Primary hepatocytes were isolated from FLAG-UOX (WT / mutant) expressed UOX
1025 KO mice at 4 weeks post AAV injection. In brief, mice were anesthetized by 1% Pell-
1026 tobarbitalum Natrium (AMRESCO, USA), and then its liver was perfused with Krebs

1027 Ringer with Glucose (KRG) buffer to remove blood, followed by type IV collagenase
1028 (C5138, Sigma) containing KRG buffer to digest collagens. Then mouse liver was
1029 harvested and cut into pieces, and filtered through a 70 μm cell strainer (352350, Falcon)
1030 to remove tissue debris. The hepatocytes were separated by 3 times 50 g centrifugation
1031 for 4 min. The cell pellet was resuspended in DMEM containing 10% FBS and 1% P/S,
1032 and cultured at 37°C, 5% CO₂.

1033

1034 **UOX purification from mouse primary hepatocytes**

1035 FLAG-UOX (WT/mutant) expressed primary hepatocytes were treated with DMSO/10
1036 mM 3-AT (A601149-0025, BBI) containing DMEM for 12 h. Cells were washed with
1037 PBS twice and then scraped from dishes in buffer C (50 mM Tris pH=7.5, 150 mM
1038 NaCl, 1% TritonX-100, 1 mM EDTA-NaOH pH=8.0, 10% glycerol with protease
1039 inhibitors). The lysate was centrifuged at 12000 rpm for 10 min at 4°C, and the
1040 supernatants were used for FLAG IP. 50 μL FLAG agarose beads were incubated with
1041 the lysate for 2 h at 4°C to enrich FLAG-UOX. Then, the FLAG beads were washed
1042 with the buffer C for 6 times and 150 μL 0.5 mg/mL FLAG peptide dissolved in buffer
1043 C were used to elute FLAG-UOX from beads. The eluate was further diluted with 5 mL
1044 TBS buffer (20 mM Tris, 150 mM NaCl, pH 7.5) and concentrated by using Amicon 5
1045 mL concentrators (10 kDa cutoffs). The final product was quantified by BCA protein
1046 assay kit.

1047

1048 **IAA-alkyne labeling of free cystines in UOX**

1049 10 μL 1 mg/mL FLAG-UOX were mixed with 10 μL 0.8% SDS dissolved in PBS at
1050 room temperature for 10 min to denature UOX and fully expose cystines. IAA-alkyne
1051 was used to label free cystines¹¹⁸. DMSO dissolved IAA-alkyne was added to protein
1052 solution at 5 mM final concentration and the mixture was incubated at room
1053 temperature for 30 min. 100 μL methanol-chloroform solution were added to reaction
1054 mixture and vortex 10 s to precipitate proteins from the mixture. Proteins were
1055 separated by 12000 rpm centrifugation at 4°C for 10 min. The protein precipitates were
1056 washed by ice-cold methanol and then resuspended in 20 μL 0.4% SDS in PBS with

1057 sonication. IAA-alkyne labeled proteins were clicked with 200 μ M Cy5-azide (777323,
1058 Sigma) or biotin-azide (T41046, TargetMol) at 29°C for 30 min. The reaction solutions
1059 were mixed with 4 \times loading and subjected to SDS-PAGE followed by fluorescence
1060 imaging and immunoblot.

1061

1062 **EM samples preparation and imaging**

1063 Animal samples were fixed at room temperature for 2 hours using 2.5% glutaraldehyde
1064 (#G5882, Sigma-Aldrich) in 0.1 M PB buffer (pH 7.4). Following four 10-minute
1065 washes with 0.1 M PB, samples were post-fixed with 1% OsO₄ in 0.1 M PB containing
1066 0.8% K₄Fe(CN)₆ for one hour in the dark. They were then rinsed again extensively with
1067 ultrapure water. Dehydration was carried out through a graded ethanol series (30%,
1068 50%, 70%, 85%, 95%, and 100%; 6 minutes per step) and two changes of acetone
1069 (100%, 8 minutes each). The tissue blocks were then infiltrated gradually with EMBED
1070 812 resin (#14120, Electron Microscopy Sciences). Polymerization of the resin was
1071 performed at 65 °C for 24 hours. The resin blocks were trimmed and sectioned with an
1072 ultramicrotome (UC7, Leica Microsystems) using a diamond knife (Ultra 35°, Diatome,
1073 Switzerland). Ultrathin sections (75 nm) were collected on formvar-film-coated single-
1074 slot grids, stained with uranyl acetate and lead citrate, and examined under a
1075 transmission electron microscope (Tecnai G2 Spirit BioTWIN, FEI) operating at 120
1076 kV. Digital images were acquired with a Gatan 832 CCD camera (Gatan, Pleasanton,
1077 CA).

1078

1079 **Quantum mechanics/Molecular mechanics simulation**

1080 The initial conformation for the MD simulations was taken from the cryo-EM-resolved
1081 tetrameric structure of UOX. Protons are added to the structure with PDBFixer
1082 toolkit¹¹⁹ and Open Babel¹²⁰. The periodic water box and neutralizing ions were
1083 constructed using the tleap module. The ff14SB force field¹²¹ was applied to the protein,
1084 while the TIP3P¹²² model was used for water molecules and ions. All molecular
1085 dynamics simulations were performed with the Amber20¹²³ software package.

1086

1087 A positional restraint with a force constant of 5.0 kcal/mol was first applied to the
1088 protein and reactant molecules during 5000 steps of energy minimization, followed by
1089 another minimization of 1000 steps with a reduced force constant of 2.0 kcal/mol.
1090 Simulations were carried out at a temperature of 300 K and a pressure of 1 bar. To
1091 prevent the small molecules from diffusing out of the binding pocket, an additional
1092 positional restraint with a force constant of 2.0 kcal/mol was applied. The system then
1093 underwent a 100 ps heating phase, a 100 ps pressure equilibration, and a 2 ns
1094 equilibration run, resulting in the MD-equilibrated structure of UOX in complex with
1095 its substrate. The RMSD calculations in this section were performed with reference to
1096 the initial structure of UOX in complex with the reactant substrate. The interface
1097 residues used for RMSD calculations were defined as the heavy atoms of residues
1098 numbered 68–105, 119–131, 146–151, 199–206, and 267–281 in each monomer of the
1099 initial structure PDB file.

1100

1101 Subsequently, key intermediate and transition state structures reported in the
1102 reference¹²⁴ were aligned to the corresponding atoms of the system. The atomic
1103 coordinates of the intermediates, as reported in the literature, were fixed, and the
1104 resulting structures were subjected to the same 6000-step minimization protocol
1105 described above. Following minimization, a 100 ps equilibration simulation was
1106 performed using the QM/MM interface between sander in AmberTools¹²³ and
1107 ORCA^{125,126}, externally coupled with the xTB software package¹²⁷ employing the
1108 GFN2-xTB¹²⁸ semiempirical method for the QM region. In this section, RMSD
1109 calculations were carried out using the MD-equilibrated structure of UOX in complex
1110 with the reactant substrate as the reference, with interface residues defined in the same
1111 manner.

1112

1113 **Sequence alignment and phylogenetic tree**

1114 For the sequence alignment of UOX among mammals that has been reported the
1115 presence of putative UOX-derived crystalloid inclusions, their amino acid sequences
1116 were downloaded from Uniprot before being aligned in CLUSTALW¹²⁹

1117 (<https://www.genome.jp/tools-bin/clustalw>). The result was visualized in ESPrict 3.0
1118 ¹³⁰.

1119

1120 For the sequence alignment of UOX in Chordata, the BLASTP search against UOX
1121 from the phylum Chordata was performed using the NCBI BLASTP model ¹³¹. The
1122 RefSeq protein database ¹³² (refseq_protein) was selected as the reference, with an E-
1123 value threshold of $< 1e-5$. Hits with a query coverage below 70% were excluded. All
1124 retrieved sequences, along with the target UOX sequence, were aligned using MUSCLE
1125 (v3.8.31) ¹³³ for multiple sequence alignment. Sequence logos were generated using
1126 WebLogo 3 ⁷⁰.

1127

1128 Based on the alignment, the residue variations at 11 positions (100, 101, 123, 147, 148,
1129 202, 203, 274, 275, 81, and 82) that may be involved in UOX assembly formation were
1130 analyzed. Phylogenetic relationships among the chordate species present in the RefSeq
1131 protein dataset were extracted from the Open Tree of Life ¹³⁴ using the R package rotl
1132 (v3.1.0) ¹³⁵. Mutations known and inferred not to affect assembly formation (L81F,
1133 R82K, N148S, R202Q) were excluded from further analysis. The resulting
1134 phylogenetic tree was visualized and annotated with mutation profiles using the R
1135 package ggtree (v3.16.0) ¹³⁶.

1136

1137 **LC-MS/MS analysis of UOX oxidation**

1138 The protein samples were separated using SDS-PAGE (3-5 μ g/lane). The gel slices
1139 were incubated with dithiothreitol (10 mM) at 37°C for 1 h, then subsequently alkylated
1140 with iodoacetamide (20 mM) at 37°C for 30 min in the dark. In-gel digestion was
1141 performed using trypsin, Glu-C and chymotrypsin (w:w = 1:40) at 37°C for 16 h,
1142 respectively. After digestion, the resulting peptides were extracted from the gel using
1143 acetonitrile and subsequently lyophilized. The peptides were desalted using C18
1144 columns (ThermoFisher, SOLA μ), eluted with acetonitrile (80% v/v) containing formic
1145 acid (0.1% v/v) and subsequently lyophilized.

1146 The lyophilized tryptic peptides were reconstituted with formic acid (0.1% v/v) and

1147 injected into an LC-MS/MS system. This system consisted of an TimsTOF Pro mass
1148 spectrometer (Bruker) coupled to a NanoElute nano-LC system. The mobile phase was
1149 composed of water with formic acid (0.1% v/v) as solvent A and acetonitrile with formic
1150 acid (0.1% v/v) as solvent B. All samples were then separated on a 15 cm C18 analytical
1151 column (EVOSEP, EV-1106) at a passive split flow of 500 nL/min for 75 min. The
1152 separation using NanoElute nano-LC involved a linear gradient of 2-12% solvent B
1153 over 10 min, followed by 12-35% solvent B over 45 min, 35-45% solvent B over 10
1154 min, 45-95% solvent B for 1 min and 95% solvent B for 9 min.


1155 The raw LC-MS/MS data were processed with PEAKS Online (Bioinformatics
1156 Solutions). The data searched against a database containing target sequences. The
1157 search using PEAKS Online followed the standard sequence database search workflow.
1158 The precursor mass tolerance was set to 20 ppm and the fragment mass tolerance was
1159 set to 0.05 Da. The maximum number of missed cleavages was set to 1. The maximum
1160 number of modifications was set to 5. Carbamidomethylation of cysteine was defined
1161 as fixed modification. The variable modifications included:

- 1162 1) oxidation of any residues (MW +15.99 Da)
- 1163 2) oxidation of cysteine (MW +47.98 Da, -15.99 Da, +31.98 Da)
- 1164 3) oxidation of tryptophan, tyrosine and phenylalanine (MW +31.98 Da)
- 1165 4) oxidation of methionine (MW +31.98 Da, -31.98 Da)
- 1166 5) oxidation of histidine (MW -21.99 Da)
- 1167 6) oxidation of arginine (MW -42.99 Da, +13.99 Da)
- 1168 7) oxidation of isoleucine, leucine, valine, proline glutamine and glycine (MW +13.99
1169 Da)
- 1170 8) oxidation of glutamic acid (MW -29.99 Da, +13.99 Da)
- 1171 9) oxidation of aspartic acid (MW +29.99 Da)

1172
1173

1174 **Figure Legends of Extended Data Figures and Tables**

1175



1176


1177 **Supplementary Figure 1: Cryo-electron tomography of mouse liver tissue.**

1178 **a**, Workflow for cryo-electron tomography sample preparation for tissues and data
1179 acquisition from mouse liver tissues.

1180 **b-f**, Representative tomograms acquired from mouse livers prepared from the workflow
1181 in (a). Yellow arrowheads indicate the supramolecular UOX assembly. Pero,
1182 peroxisome. Scale bars, 100 nm.

1183 **g**, 3D rendering of the segmentation from the tomogram shown in **(f)**. Yellow,
1184 mitochondrion. Magenta, ER membrane. Grey, ribosome. Green, peroxisome. Orange,
1185 the UOX assembly. Scale bars, 100 nm.

1186 **h-i**, Different Z-axis slices of the UOX assembly at the top **(h)** and side **(i)** views from
1187 tomograms. Scale bars, 10 nm.
1188



1189


1190 **Supplementary Figure 2: The subtomogram averaging of mouse UOX assembly**

1191 **a**, Workflow of subtomogram averaging of mouse UOX assembly.

1192 **b**, Fourier shell correlation (FSC) curve of final map where FSC = 0.143 is used as a
1193 cutoff to estimate resolution.

1194 **c**, Final density map colored according to local resolution (Å) as indicated by the color
1195 bar. Left, side view. Right, top view.

1196 **d**, (Top) Atomic model of mouse UOX predicted by AlphaFold2 fitted into the final
1197 density map. (Bottom) Representative fit of four α -helices highlighting agreement
1198 between model and density.
1199
1200



1201


1202 **Supplementary Figure 3: Structural organization of the mouse UOX helical fiber.**

1203 **a**, 2D surface lattice plot of the UOX fiber, with z-height plotted against the azimuthal
1204 angle. The centers of individual subunits are represented as dots, with the two strands
1205 colored black and red. Subunit indices are annotated.

1206 **b**, Left, high-resolution density map of UOX fibers with the subunit *i* colored green.
1207 Right, schematic of subunit *i* and its directly interacting neighbors. Three interfaces are
1208 labeled in blue as A, B, and C.

1209 **c**, Relative orientation of subunit *i* and *i*+1, illustrating the helical twist and rise applied.

1210



1211

1212 **Supplementary Figure 4: Structure determination of mouse UOX tetramer in apo**
1213 **state and substrate-bound state.**

1214 **a**, SDS-PAGE with Coomassie Blue staining. Fraction 1 (F1) and fraction 2 (F2) are
1215 from size exclusion chromatography shown in (b). P, precipitation. S, supernatant. FT,
1216 flowthrough. W, wash. R0, resin before elution. E, eluate. R1, resin after elution.

1217 **b**, Size exclusion chromatogram profile (Superdex 200 Increase 10/300 GL) of mouse

1218 UOX in the apo state.

1219 **c**, Atomic model of the UOX tetramer colored by RMSD between the apo state and
1220 substrate-bound state.

1221 **(d–h)** Refers to the cryo-EM processing of UOX in the apo state, and **(i–m)** in the
1222 substrate-bound state.

1223 **d, i**, Representative micrographs.


1224 **e, j**, Data processing workflow, including representative 2D class averages, 3D
1225 classification steps and final reconstructed map.

1226 **f, k**, Fourier shell correlation (FSC) curves of final map where FSC = 0.143 (black line)
1227 is used as a cutoff to estimate resolution.

1228 **g, l**, Final density map colored according to local resolution (Å) as indicated by the
1229 color bar.

1230 **h, m**, Density of substrate-binding pocket and its neighboring residues, shown with the
1231 fitted atomic model.

1232



1233

1234 **Supplementary Figure 5: Isolation of mouse peroxisomes and single-particle cryo-**
 1235 **EM structure determination of UOX assembly.**

1236 **a**, Data processing workflow for the mouse UOX assembly, including 2D class averages
 1237 and 3D refinement steps.

1238 **b**, Fourier shell correlation (FSC) curves of final map where FSC = 0.143 (black line)
1239 is used as a cutoff to estimate resolution.

1240 **c**, Final density map of a single UOX fiber within the assembly, shown in side (left)
1241 and top (right) views.

1242 **d**, Western blot analysis of UOX from fractions collected after Optiprep density
1243 gradient centrifugation. 600S, 2700S, and 37000S denote supernatants from sequential
1244 centrifugations of mouse liver homogenate at 600 g, 2,700 g, and 37,000 g, respectively.
1245 LM, sample loaded onto the gradient; LM2+, combined LM1-LM2 and core fractions.

1246 **e**, Low-magnification view of a grid square with isolated peroxisomes. Scale bars, 10
1247 μm .

1248 **f**, Representative image of grid holes containing isolated peroxisomes. Scale bars, 1 μm .

1249 **g**, Representative cryo-EM micrograph of isolated peroxisomes. Scale bars, 50 nm.

1250 **h**, Representative 2D classification results of the UOX assembly. Scale bars, 40 nm.

1251 **i**, Final density map colored according to local resolution (\AA) as indicated by the color
1252 bar.


1253 **j**, Visual representation of layers (core, LM1-LM5) after Optiprep density gradient
1254 centrifugation.

1255 **k**, Atomic model of the UOX tetramer colored by RMSD between free tetramers and
1256 assembly-incorporated tetramers.

1257 **l**, Western blot of UOX in different fractions of isolated peroxisomes after pelleting. S,
1258 supernatant. P, precipitation. Total, samples before centrifugation.

1259 **m**, Quantification of band intensities from (l). Data are presented as mean \pm SD;
1260 individual points represent technical replicates.

1261




1262

1263 **Supplementary Figure 6: Assembly formation and precipitation of purified UOX**

1264 **a-b**, Representative electron micrographs showing high-order assembly of purified
1265 UOX *in vitro*. Scale bars, 50 nm.

1266 **c-d**, Representative electron micrographs showing precipitation of purified UOX *in*
1267 *vitro*. Scale bars, 50 nm.

1268




1269

274 275

1270 **Supplementary Figure 7: Sequence alignment of UOX from mammals that has**
 1271 **been reported the presence of putative UOX-derived crystalloid inclusions.**

1272 UOX protein sequences from mouse (UniProt ID: P25688), rat (UniProt ID: P09118),
1273 pig (UniProt ID: P16164), dog (UniProt ID: Q5FZI9), rabbit (UniProt ID: P11645),
1274 bovine (UniProt ID: Q3MHG7), macaque (UniProt ID: Q8MKJ3), cat (UniProt ID:
1275 M3XBL4), guinea pig (UniProt ID: H0W3D6), sheep (UniProt ID: W5PWL0), hamster
1276 (UniProt ID: A0A1U8CNN0) were aligned using CLUSTALW ¹²⁹. The result was
1277 visualized with ESPript 3.0 ¹³⁰, with key residues directly involved in UOX assembly
1278 formation highlighted in black frames.
1279



1280

1281

Supplementary Figure 8: The phylogenetic tree of UOX and mutation patterns of key UOX assembly-related residues across chordates.

1282

1283


a, Phylogenetic tree of UOX in Chordata and amino acid substitutions at 11 positions

1284 (100, 101, 123, 147, 148, 202, 203, 274, 275, 81, 82) that are closely associated with
1285 the assembly-forming of UOX. Each column represents one key residue, and each row
1286 represents a species. Different colors indicate different types of amino acid substitutions;
1287 white denotes no mutation at the corresponding position, and black indicates that the
1288 UOX sequence could not be identified in that species, suggesting a possible gene loss.
1289 Substitutions known and inferred not to affect assembly formation (L81F, R82K,
1290 N148S, R202Q) were excluded. Each position is annotated with the corresponding
1291 wild-type amino acid. Major evolutionary clades—such as Mammalia, Amniota, and
1292 Tetrapoda—are labeled alongside the phylogenetic tree.

1293 **b**, Sequence conservation analysis of specific UOX motifs in Mammalia (n = 313),
1294 generated with WebLogo3⁷⁰. Residues directly involved in interactions are boxed in
1295 black. Numbers indicate corresponding residue positions in mouse UOX (UniProt ID:
1296 P25688).

1297

1298




1299

1300 **Supplementary Figure 9: Quantum mechanics/molecular mechanics simulation**
1301 **for UOX catalysis.**

1302 **a-g**, RMSD plot of UOX in complex with its substrate UA during the simulation of
1303 several reported transition states (TS) and intermediate states (INT) ¹²⁴, using the MD-
1304 equilibrated structure as the reference. The superscript “t” represents triplet, and the
1305 superscript “s” represents singlet.

1306



1307

1308 **Supplementary Figure 10: Mutant UOX maintained normal tetramer formation**
 1309 **and catalytic activity while completely abolishing high-order assembly.**

1310 **a**, SDS-PAGE with Coomassie Blue staining. Fraction1-3 (F1-F3) correspond to size
 1311 exclusion chromatography fractions shown in (b). P, precipitation. S, supernatant. FT,
 1312 flowthrough. W, wash. R0, resin before elution. E, eluate. R1, resin after elution.

1313 **b**, Size exclusion chromatogram profile (Superdex 200 Increase 10/300 GL) of mutant
 1314 UOX in the apo state.

1315 **c**, Enzyme kinetics of wild-type UOX and mutant UOX. The rate (specific activity) of
 1316 UA oxidation was measured by the linear decrease in absorbance at 293 nm. The data

1317 were fitted to the Michaelis-Menten equation by GraphPad Prism 9 to determine the
1318 k_{cat} and K_m values. The data are presented as the mean \pm SD of at least three independent
1319 experiments.

1320 **d**, Schematic of CRISPR–Cas9-mediated liver-specific knockout and rescue strategy in
1321 mice. The timeline illustrates key steps: AAV (Adeno-Associated Virus) injection,
1322 serum collection, and primary hepatocyte isolation.

1323 **e**, Western blot analysis of FLAG-UOX and tubulin (loading control) in liver extracts
1324 from wild-type and UOX rescue mice.

1325 **f-g**, Representative TEM images of liver from mutant UOX rescue mice. Yellow
1326 arrowheads indicate peroxisomes lacking UOX assembly. Scale bars, 200 nm.

1327 **h-i**, Representative tomograms acquired from high-pressure frozen livers of mutant
1328 UOX rescue mice. Yellow arrowheads indicate peroxisomes lacking UOX assembly.

1329 Scale bars, 100 nm.

1330

1331 **Supplementary Table 1:** Cryo-ET and cryo-EM data, map and atomic model
 1332 statistics
 1333

	UOX fiber <i>in situ</i> (EMD- 68844)	UOX fiber <i>ex vivo</i> (EMD- 68841) (PDB 23BU)	UOX homotetramers (apo) (EMD-68839) (PDB 23BS)	UOX homotetramers (urate bound) (EMD-68840) (PDB 23BT)
Data collection and processing				
Magnification	64,000×	130,000×	165,000×	165,000×
Voltage (kV)	300	200	300	300
Electron exposure (e/Å ²)	110	60	60	60
Defocus range (μm)	-4.0 to -6.0	-1.0 to -2.0	-1.0 to -1.4	-1.0 to -1.4
Pixel size (Å)	1.37	0.93	0.74	0.74
Symmetry imposed	Helix	Helix, D1	D2	D2
Initial particle images (no.)	25,040	324,169	3,074,690	2,374,447
Final particle images (no.)	17,221	219,322	101,075	304,325
	(22 tomograms)			
Map resolution (Å)	7.3	3.64	2.79	2.42
FSC threshold	0.143	0.143	0.143	0.143
Map resolution range (Å)	6.5-11.1	3.4-3.7	2.8-3.3	2.2-2.8
Refinement				
Initial model used		AlphaFold2	AlphaFold2	AlphaFold2
Model resolution (Å)		3.7	2.8	2.4
FSC threshold		0.143	0.143	0.143
Model resolution range (Å)			2.8-3.2	2.4-2.7
Map sharpening <i>B</i> factor (Å ²)		-127.9	-28.1794	-102.2
Model composition				
Non-hydrogen atoms		9344	9276	9324
Protein residues		1148	1140	1140
Ligands		URC: 4	-	URC: 4
<i>B</i> factors (Å ²)				
Protein		77.26	127.4	47.59
Ligand		39.53	-	39.53

R.m.s. deviations			
Bond lengths (Å)	0.003	0.003	0.004
Bond angles (°)	0.748	0.541	0.59
Validation			
MolProbity score	2.05	1.65	1.42
Clashscore	8.34	6.67	5.04
Poor rotamers	3.07	0.00	0.00
(%)			
Ramachandran plot			
Favored (%)	96.49	95.94	97.17
Allowed (%)	3.51	4.06	2.83
Disallowed (%)	0.00	0.00	0.00

1334

1335

1336

1337 **Supplementary Table S2**: List of frequently detected mouse peroxisomal proteins
1338 (high detection frequency) and their Q-scores (Top12) by DiffFit
1339
1340

1341 **Supplementary Table S3:** The amino acid sequence of assembly-disrupting mutant
1342 *Mus musculus* UOX used in this study (The replaced sequences compared to WT
1343 UOX are colored in red)
1344

Protein	Amino acid sequence
UOX (mutant)	MAHYHDNYGKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVAT SVQLTLRSKKDYLHGDNSDIIPDTIKNTVHVLAKLRGIRNIETFAMN ICEHFLSSFNVTRAHVYVEEVPWKRFEKNGIKHVHAFIHTPTGTHF CEVEQMRNGPPVIHSGIKDLKVLKTTQSGFEGFLKDQFTTLPEVKDR CFATQVYCKWRYKNFSGLQEVRSHPKFEAIWGAVRDIVLQKFAGP YDKGEYSPSVQKTLYDIQVLSLSQLPEIEDMEISLPNIHYFNIDMSKM GLINKEEVLLPLDNPYGKITGTVKRKLPSRL

1345
1346

1347 **Supplementary Table S4:** Enzyme kinetic parameters of wild-type and assembly
1348 disrupting mutant mouse UOX (Data are presented as mean \pm SD across three
1349 independent assays)

1350

	K_m (μM)	k_{cat} (s^{-1})	k_{cat}/K_m ($\text{s}^{-1} \cdot \text{M}^{-1}$)
UOX (WT)	69.7 ± 6.4	2.86 ± 0.25	$(4.15 \pm 0.69) \times 10^4$
UOX (mutant)	68.7 ± 7.7	2.97 ± 0.28	$(4.36 \pm 0.63) \times 10^4$

1351

1352

1353 **Supplementary Video 1:** The *in situ* structure of mouse UOX assembly in liver
1354 tissue
1355
1356

1357 **References**

- 1358 1. Model, M.A., Hollembeak, J.E., and Kurokawa, M. (2021). Macromolecular Crowding: a
1359 Hidden Link Between Cell Volume and Everything Else. *Cellular Physiology and*
1360 *Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and*
1361 *Pharmacology* *55*, 25-40. 10.33594/000000319.
- 1362 2. Rivas, G., and Minton, A.P. (2016). Macromolecular Crowding In Vitro, In Vivo, and In
1363 Between. *Trends in Biochemical Sciences* *41*, 970-981. 10.1016/j.tibs.2016.08.013.
- 1364 3. Clegg, J.S. (1984). Properties and metabolism of the aqueous cytoplasm and its
1365 boundaries. *The American Journal of Physiology* *246*, R133-151.
1366 10.1152/ajpregu.1984.246.2.R133.
- 1367 4. Kim, Y.C., Best, R.B., and Mittal, J. (2010). Macromolecular crowding effects on protein-
1368 protein binding affinity and specificity. *The Journal of Chemical Physics* *133*, 205101.
1369 10.1063/1.3516589.
- 1370 5. McGuffee, S.R., and Elcock, A.H. (2010). Diffusion, crowding & protein stability in a
1371 dynamic molecular model of the bacterial cytoplasm. *PLoS computational biology* *6*,
1372 e1000694. 10.1371/journal.pcbi.1000694.
- 1373 6. Huang, J.-H., and Ferrell, J.E., Jr. (2026). How does cytoplasmic crowding affect reaction
1374 rates? *Molecular Cell*. 10.1016/j.molcel.2025.12.007.
- 1375 7. Alfano, C., Fichou, Y., Huber, K., Weiss, M., Spruijt, E., Ebbinghaus, S., De Luca, G., Morando,
1376 M.A., Vetri, V., Temussi, P.A., and Pastore, A. (2024). Molecular Crowding: The History and
1377 Development of a Scientific Paradigm. *Chemical Reviews* *124*, 3186-3219.
1378 10.1021/acs.chemrev.3c00615.
- 1379 8. Li, P., Banjade, S., Cheng, H.-C., Kim, S., Chen, B., Guo, L., Llaguno, M., Hollingsworth, J.V.,
1380 King, D.S., Banani, S.F., et al. (2012). Phase transitions in the assembly of multivalent
1381 signalling proteins. *Nature* *483*, 336-340. 10.1038/nature10879.
- 1382 9. Brangwynne, C.P., Eckmann, C.R., Courson, D.S., Rybarska, A., Hoege, C., Gharakhani, J.,
1383 Jülicher, F., and Hyman, A.A. (2009). Germline P Granules Are Liquid Droplets That Localize
1384 by Controlled Dissolution/Condensation. *Science* *324*, 1729-1732.
1385 doi:10.1126/science.1172046.
- 1386 10. Lafontaine, D.L.J., Riback, J.A., Bascetin, R., and Brangwynne, C.P. (2021). The nucleolus as
1387 a multiphase liquid condensate. *Nature Reviews. Molecular Cell Biology* *22*, 165-182.
1388 10.1038/s41580-020-0272-6.
- 1389 11. Protter, D.S.W., and Parker, R. (2016). Principles and Properties of Stress Granules. *Trends*
1390 *in Cell Biology* *26*, 668-679. 10.1016/j.tcb.2016.05.004.
- 1391 12. Munishkina, L.A., Ahmad, A., Fink, A.L., and Uversky, V.N. (2008). Guiding protein
1392 aggregation with macromolecular crowding. *Biochemistry* *47*, 8993-9006.
1393 10.1021/bi8008399.
- 1394 13. Schönherr, R., Rudolph, J.M., and Redecke, L. (2018). Protein crystallization in living cells.
1395 *Biological Chemistry* *399*, 751-772. doi:10.1515/hsz-2018-0158.
- 1396 14. Wu, Y., Qin, C., Du, W., Guo, Z., Chen, L., and Guo, Q. (2023). A practical multicellular
1397 sample preparation pipeline broadens the application of in situ cryo-electron tomography.
1398 *Journal of Structural Biology* *215*, 107971. 10.1016/j.jsb.2023.107971.
- 1399 15. Tang, X., Qu, L., Wilfling, F., Beck, F., Ernst, O.P., Schulman, B.A., Baumeister, W., and
1400 Enenkel, C. Metabolically regulated proteasome supramolecular organization in

- 1401 situ. *Cell* 10.1016/j.cell.2025.12.035.
- 1402 16. Hyman, A.A., Weber, C.A., and Jülicher, F. (2014). Liquid-Liquid Phase Separation in
1403 Biology. *Annual Review of Cell and Developmental Biology* 30, 39-58.
1404 <https://doi.org/10.1146/annurev-cellbio-100913-013325>.
- 1405 17. Castellana, M., Wilson, M.Z., Xu, Y., Joshi, P., Cristea, I.M., Rabinowitz, J.D., Gitai, Z., and
1406 Wingreen, N.S. (2014). Enzyme clustering accelerates processing of intermediates through
1407 metabolic channeling. *Nature Biotechnology* 32, 1011-1018. 10.1038/nbt.3018.
- 1408 18. Liu, J.-L. (2016). The Cytoophidium and Its Kind: Filamentation and Compartmentation of
1409 Metabolic Enzymes. *Annual Review of Cell and Developmental Biology* 32, 349-372.
1410 10.1146/annurev-cellbio-111315-124907.
- 1411 19. Petrovska, I., Nüske, E., Munder, M.C., Kulasegaran, G., Malinowska, L., Kroschwald, S.,
1412 Richter, D., Fahmy, K., Gibson, K., Verbavatz, J.-M., and Alberti, S. (2014). Filament
1413 formation by metabolic enzymes is a specific adaptation to an advanced state of cellular
1414 starvation. *eLife* 3, e02409. 10.7554/eLife.02409.
- 1415 20. Labesse, G., Alexandre, T., Vaupré, L., Salard-Arnaud, I., Him, Joséphine Lai K., Raynal, B.,
1416 Bron, P., and Munier-Lehmann, H. (2013). MgATP Regulates Allostery and Fiber Formation
1417 in IMPDHs. *Structure* 21, 975-985. 10.1016/j.str.2013.03.011.
- 1418 21. Sendker, F.L., Lo, Y.K., Heimerl, T., Bohn, S., Persson, L.J., Mais, C.-N., Sadowska, W., Paczia,
1419 N., Nußbaum, E., del Carmen Sánchez Olmos, M., et al. (2024). Emergence of fractal
1420 geometries in the evolution of a metabolic enzyme. *Nature*, 1-7. 10.1038/s41586-024-
1421 07287-2.
- 1422 22. Bauerlein, F.J.B., and Baumeister, W. (2021). Towards Visual Proteomics at High Resolution.
1423 *J Mol Biol* 433, 167187. 10.1016/j.jmb.2021.167187.
- 1424 23. Parlakgöl, G., Arruda, A.P., Pang, S., Cagampan, E., Min, N., Güney, E., Lee, G.Y., Inouye, K.,
1425 Hess, H.F., Xu, C.S., and Hotamışlıgil, G.S. (2022). Regulation of liver subcellular
1426 architecture controls metabolic homeostasis. *Nature* 603, 736-742. 10.1038/s41586-022-
1427 04488-5.
- 1428 24. Ilacqua, N., Anastasia, I., Raimondi, A., Lemieux, P., De Aguiar Vallim, T.Q., Toth, K., Koonin,
1429 E.V., and Pellegrini, L. (2022). A three-organelle complex made by wrapPER contacts with
1430 peroxisomes and mitochondria responds to liver lipid flux changes. *Journal of Cell Science*
1431 135. 10.1242/jcs.259091.
- 1432 25. Bernhard, W., and Rouiller, C. (1956). Microbodies and the problem of mitochondrial
1433 regeneration in liver cells. *The Journal of Biophysical and Biochemical Cytology* 2, 355-
1434 360. 10.1083/jcb.2.4.355.
- 1435 26. De Duve, C., and Baudhuin, P. (1966). Peroxisomes (microbodies and related particles).
1436 *Physiological Reviews* 46, 323-357. 10.1152/physrev.1966.46.2.323.
- 1437 27. Gansler, H.d., and Rouiller, C. (2010). Modifications physiologiques et pathologiques du
1438 chondriome (Part 4 of 4): Etude au microscope électronique. *Schweizerische Zeitschrift*
1439 *für allgemeine Pathologie und Bakteriologie* 19, 238-243. 10.1159/000317715.
- 1440 28. Shnitka, T.K. (1966). Comparative ultrastructure of hepatic microbodies in some mammals
1441 and birds in relation to species differences in uricase activity. *Journal of Ultrastructure*
1442 *Research* 16, 598-625. [https://doi.org/10.1016/S0022-5320\(66\)80009-6](https://doi.org/10.1016/S0022-5320(66)80009-6).
- 1443 29. Hruban, Z., and Swift, H. (1964). URICASE: LOCALIZATION IN HEPATIC MICROBODIES.
1444 *Science (New York, N.Y.)* 146, 1316-1318. 10.1126/science.146.3649.1316.

- 1445 30. Tsukada, H., Mochizuki, Y., and Fujiwara, S. (1966). The nucleoids of rat liver cell
1446 microbodies. Fine structure and enzymes. *The Journal of Cell Biology* *28*, 449-460.
1447 10.1083/jcb.28.3.449.
- 1448 31. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool,
1449 K., Bates, R., Žídek, A., Potapenko, A., et al. (2021). Highly accurate protein structure
1450 prediction with AlphaFold. *Nature* *596*, 583-589. 10.1038/s41586-021-03819-2.
- 1451 32. Yifrach, E., Fischer, S., Oeljeklaus, S., Schuldiner, M., Zalckvar, E., and Warscheid, B. (2018).
1452 Defining the Mammalian Peroxisomal Proteome. *Sub-Cellular Biochemistry* *89*, 47-66.
1453 10.1007/978-981-13-2233-4_2.
- 1454 33. Luo, D., Alsuwaykit, Z., Khan, D., Strnad, O., Isenberg, T., and Viola, I. (2025). DiffFit:
1455 Visually-Guided Differentiable Fitting of Molecule Structures to a Cryo-EM Map. *IEEE*
1456 *Transactions on Visualization and Computer Graphics* *31*, 558-568.
1457 10.1109/TVCG.2024.3456404.
- 1458 34. Pintilie, G., Zhang, K., Su, Z., Li, S., Schmid, M.F., and Chiu, W. (2020). Measurement of
1459 atom resolvability in cryo-EM maps with Q-scores. *Nature Methods* *17*, 328-334.
1460 10.1038/s41592-020-0731-1.
- 1461 35. Kahn, K., Serfozo, P., and Tipton, P.A. (1997). Identification of the True Product of the Urate
1462 Oxidase Reaction. *Journal of the American Chemical Society* *119*, 5435-5442.
1463 10.1021/ja970375t.
- 1464 36. Modrić, N., Derome, A.E., Ashcroft, S.J.H., and Poje, M. (1992). Tracing and identification
1465 of uricase. Reaction intermediates.: A direct ¹³C-NMR/isotope-labelling evidence.
1466 *Tetrahedron Letters* *33*, 6691-6694. 10.1016/S0040-4039(00)61021-3.
- 1467 37. Völkl, A., Baumgart, E., and Fahimi, H.D. (1988). Localization of urate oxidase in the
1468 crystalline cores of rat liver peroxisomes by immunocytochemistry and immunoblotting.
1469 *Journal of Histochemistry & Cytochemistry* *36*, 329-336. 10.1177/36.4.3346536.
- 1470 38. Usuda, N., Reddy, M.K., Hashimoto, T., Rao, M.S., and Reddy, J.K. (1988). Tissue specificity
1471 and species differences in the distribution of urate oxidase in peroxisomes. *Laboratory*
1472 *Investigation; a Journal of Technical Methods and Pathology* *58*, 100-111.
- 1473 39. Angermüller, S., and Fahimi, H.D. (1986). Ultrastructural cytochemical localization of
1474 uricase in peroxisomes of rat liver. *Journal of Histochemistry & Cytochemistry* *34*, 159-
1475 165. 10.1177/34.2.3080517.
- 1476 40. Leighton, F., Poole, B., Lazarow, P.B., and De Duve, C. (1969). THE SYNTHESIS AND
1477 TURNOVER OF RAT LIVER PEROXISOMES : I. Fractionation of Peroxisome Proteins. *Journal*
1478 *of Cell Biology* *41*, 521-535. 10.1083/jcb.41.2.521.
- 1479 41. Wang, C., Jiang, W., Leitz, J., Yang, K., Esquivies, L., Wang, X., Shen, X., Held, R.G., Adams,
1480 D.J., Basta, T., et al. (2024). Structure and topography of the synaptic V-ATPase-
1481 synaptophysin complex. *Nature*, 1-6. 10.1038/s41586-024-07610-x.
- 1482 42. Zheng, W., Chai, P., Zhu, J., and Zhang, K. (2024). High-resolution in situ structures of
1483 mammalian respiratory supercomplexes. *Nature*, 1-8. 10.1038/s41586-024-07488-9.
- 1484 43. Friedman, T.B., Polanco, G.E., Appold, J.C., and Mayle, J.E. (1985). On the loss of uricolytic
1485 activity during primate evolution—I. Silencing of urate oxidase in a hominoid ancestor.
1486 *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry* *81*, 653-659.
1487 [https://doi.org/10.1016/0305-0491\(85\)90381-5](https://doi.org/10.1016/0305-0491(85)90381-5).
- 1488 44. Fujiwara, S., Ohashi, H., and Noguchi, T. (1987). Comparison of intraperoxisomal

- 1489 localization form and properties of amphibian (*Rana catesbeiana*) uricase with those of
1490 other animal uricases. *Comparative Biochemistry and Physiology. B, Comparative*
1491 *Biochemistry* *86*, 23-26. 10.1016/0305-0491(87)90169-6.
- 1492 45. Noguchi, T., Takada, Y., and Fujiwara, S. (1979). Degradation of uric acid to urea and
1493 glyoxylate in peroxisomes. *Journal of Biological Chemistry* *254*, 5272-5275.
1494 10.1016/S0021-9258(18)50590-1.
- 1495 46. Fujiwara, S., Nakashima, K., and Noguchi, T. (1987). Insoluble uricase in liver peroxisomes
1496 of Old World monkeys. *Comparative Biochemistry and Physiology. B, Comparative*
1497 *Biochemistry* *88*, 467-469. 10.1016/0305-0491(87)90328-2.
- 1498 47. Feng, S., Aplin, C., Nguyen, T.-T.T., Milano, S.K., and Cerione, R.A. (2024). Filament
1499 formation drives catalysis by glutaminase enzymes important in cancer progression.
1500 *Nature Communications* *15*, 1971. 10.1038/s41467-024-46351-3.
- 1501 48. Hvorecny, K.L., Hargett, K., Quispe, J.D., and Kollman, J.M. (2023). Human PRPS1 filaments
1502 stabilize allosteric sites to regulate activity. *Nature Structural & Molecular Biology* *30*, 391-
1503 402. 10.1038/s41594-023-00921-z.
- 1504 49. Colloc'h, N., el Hajji, M., Bachet, B., L'Hermite, G., Schiltz, M., Prangé, T., Castro, B., and
1505 Moron, J.P. (1997). Crystal structure of the protein drug urate oxidase-inhibitor complex
1506 at 2.05 Å resolution. *Nature Structural Biology* *4*, 947-952. 10.1038/nsb1197-947.
- 1507 50. Davies, Michael J. (2016). Protein oxidation and peroxidation. *Biochemical Journal* *473*,
1508 805-825. 10.1042/bj20151227.
- 1509 51. Celi, P., and Gabai, G. (2015). Oxidant/Antioxidant Balance in Animal Nutrition and Health:
1510 The Role of Protein Oxidation. *Frontiers in Veterinary Science* *2*. 10.3389/fvets.2015.00048.
- 1511 52. Davies, M.J. (2005). The oxidative environment and protein damage. *Biochimica et*
1512 *Biophysica Acta (BBA) - Proteins and Proteomics* *1703*, 93-109.
1513 10.1016/j.bbapap.2004.08.007.
- 1514 53. Garcia-Seisdedos, H., Empereur-Mot, C., Elad, N., and Levy, E.D. (2017). Proteins evolve
1515 on the edge of supramolecular self-assembly. *Nature* *548*, 244-247. 10.1038/nature23320.
- 1516 54. Pillai, A.S., Chandler, S.A., Liu, Y., Signore, A.V., Cortez-Romero, C.R., Benesch, J.L.P.,
1517 Laganowsky, A., Storz, J.F., Hochberg, G.K.A., and Thornton, J.W. (2020). Origin of
1518 complexity in haemoglobin evolution. *Nature* *581*, 480-485. 10.1038/s41586-020-2292-
1519 y.
- 1520 55. Grueninger, D., Treiber, N., Ziegler, M.O.P., Koetter, J.W.A., Schulze, M.-S., and Schulz, G.E.
1521 (2008). Designed Protein-Protein Association. *Science* *319*, 206-209.
1522 doi:10.1126/science.1150421.
- 1523 56. Hvorecny, K.L., and Kollman, J.M. (2023). Greater than the sum of parts:
1524 Mechanisms of metabolic regulation by enzyme filaments. *Current Opinion in Structural*
1525 *Biology* *79*, 102530. <https://doi.org/10.1016/j.sbi.2023.102530>.
- 1526 57. Park, C.K., and Horton, N.C. (2019). Structures, functions, and mechanisms of filament
1527 forming enzymes: a renaissance of enzyme filamentation. *Biophysical Reviews* *11*, 927-
1528 994. 10.1007/s12551-019-00602-6.
- 1529 58. Ramazzina, I., Folli, C., Secchi, A., Berni, R., and Percudani, R. (2006). Completing the uric
1530 acid degradation pathway through phylogenetic comparison of whole genomes. *Nature*
1531 *Chemical Biology* *2*, 144-148. 10.1038/nchembio768.
- 1532 59. Sarma, A.D., Serfozo, P., Kahn, K., and Tipton, P.A. (1999). Identification and Purification of

- 1533 Hydroxyisourate Hydrolase, a Novel Ureide-metabolizing Enzyme*. *Journal of Biological*
1534 *Chemistry* *274*, 33863-33865. 10.1074/jbc.274.48.33863.
- 1535 60. Schultz, A.C., Nygaard, P., and Saxild, H.H. (2001). Functional Analysis of 14 Genes That
1536 Constitute the Purine Catabolic Pathway in *Bacillus subtilis* and Evidence for a Novel
1537 Regulon Controlled by the PucR Transcription Activator. *Journal of Bacteriology* *183*,
1538 3293-3302. 10.1128/jb.183.11.3293-3302.2001.
- 1539 61. Sun, Z., Zhang, X., Zhao, Z., Li, X., Pang, J., and Chen, J. (2024). Recent Progress and Future
1540 Perspectives on Anti-Hyperuricemic Agents. *Journal of Medicinal Chemistry*.
1541 10.1021/acs.jmedchem.4c01260.
- 1542 62. Pui, C.-H. (2002). Rasburicase: a potent uricolytic agent. *Expert Opinion on*
1543 *Pharmacotherapy* *3*, 433-442. 10.1517/146556566.3.4.433.
- 1544 63. Schlesinger, N., Yasothan, U., and Kirkpatrick, P. (2011). Pegloticase. *Nature Reviews Drug*
1545 *Discovery* *10*, 17-18. 10.1038/nrd3349.
- 1546 64. Schlesinger, N., Pérez-Ruiz, F., and Lioté, F. (2023). Mechanisms and rationale for uricase
1547 use in patients with gout. *Nature Reviews Rheumatology* *19*, 640-649. 10.1038/s41584-
1548 023-01006-3.
- 1549 65. Duan, Y., Jiang, N., Chen, J., and Chen, J. (2021). Expression, localization and metabolic
1550 function of "resurrected" human urate oxidase in human hepatocytes. *International*
1551 *Journal of Biological Macromolecules* *175*, 30-39. 10.1016/j.ijbiomac.2021.01.163.
- 1552 66. Li, Z., Hoshino, Y., Tran, L., and Gaucher, E.A. (2022). Phylogenetic Articulation of Uric Acid
1553 Evolution in Mammals and How It Informs a Therapeutic Uricase. *Molecular Biology and*
1554 *Evolution* *39*, msab312. 10.1093/molbev/msab312.
- 1555 67. Yang, B., Luo, G., Nie, T., Ban, Z., Ning, Q., Zhang, J., Liu, X., Lin, Y., Xie, X., Chen, Q., et al.
1556 (2025). Biomimetic bioreactor for potentiated uricase replacement therapy in
1557 hyperuricemia and gout. *Frontiers in Bioengineering and Biotechnology* *12*.
1558 10.3389/fbioe.2024.1520663.
- 1559 68. Tran, L., Das, S., Zhao, L., Finn, M.G., and Gaucher, E.A. (2023). Oral Delivery of
1560 Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in
1561 Knockout Mice. *Biomacromolecules* *24*, 2003-2008. 10.1021/acs.biomac.2c01388.
- 1562 69. Gong, X., Liu, S., Xia, B., Wan, Y., Zhang, S., Zhang, B., Wang, Z., Chen, J., Xiao, F., Liang,
1563 X.-J., and Yang, Y. (2025). Oral delivery of therapeutic proteins by engineered bacterial
1564 type zero secretion system. *Nature Communications* *16*, 1862. 10.1038/s41467-025-
1565 57153-6.
- 1566 70. Crooks, G.E., Hon, G., Chandonia, J.-M., and Brenner, S.E. (2004). WebLogo: A Sequence
1567 Logo Generator: Figure 1. *Genome Research* *14*, 1188-1190. 10.1101/gr.849004.
- 1568 71. Wenjing, D., Junhan, Y., and Qiang, G. (2025). Optimized Tissue Sample Preparation for
1569 Cryo-Electron Tomography Using Serial Lift-Out. *Biophysics Reports* *0*, 0.
1570 10.52601/bpr.2025.250035.
- 1571 72. Schiøtz, O.H., Kaiser, C.J.O., Klumpe, S., Morado, D.R., Poege, M., Schneider, J., Beck, F.,
1572 Klebl, D.P., Thompson, C., and Pitzko, J.M. (2023). Serial Lift-Out: sampling the molecular
1573 anatomy of whole organisms. *Nature Methods*, 1-9. 10.1038/s41592-023-02113-5.
- 1574 73. Mastronarde, D.N. (2005). Automated electron microscope tomography using robust
1575 prediction of specimen movements. *Journal of Structural Biology* *152*, 36-51.
1576 10.1016/j.jsb.2005.07.007.

- 1577 74. Eisenstein, F., Yanagisawa, H., Kashihara, H., Kikkawa, M., Tsukita, S., and Danev, R. (2023).
1578 Parallel cryo electron tomography on in situ lamellae. *Nature Methods* *20*, 131-138.
1579 10.1038/s41592-022-01690-1.
- 1580 75. Turoňová, B., Hagen, W.J.H., Obr, M., Mosalaganti, S., Beugelink, J.W., Zimmerli, C.E.,
1581 Kräusslich, H.-G., and Beck, M. (2020). Benchmarking tomographic acquisition schemes
1582 for high-resolution structural biology. *Nature Communications* *11*, 876. 10.1038/s41467-
1583 020-14535-2.
- 1584 76. Hagen, W.J.H., Wan, W., and Briggs, J.A.G. (2017). Implementation of a cryo-electron
1585 tomography tilt-scheme optimized for high resolution subtomogram averaging. *Journal*
1586 *of Structural Biology* *197*, 191-198. 10.1016/j.jsb.2016.06.007.
- 1587 77. Khavnekar, S., Erdmann, P.S., and Wan, W. (2024). TOMOMAN: a software package for
1588 large-scale cryo-electron tomography data preprocessing, community data sharing and
1589 collaborative computing. *Journal of Applied Crystallography* *57*, 2010-2016.
1590 10.1107/S1600576724010264.
- 1591 78. Nickell, S., Förster, F., Linaroudis, A., Net, W.D., Beck, F., Hegerl, R., Baumeister, W., and
1592 Plietzko, J.M. (2005). TOM software toolbox: acquisition and analysis for electron
1593 tomography. *Journal of Structural Biology* *149*, 227-234. 10.1016/j.jsb.2004.10.006.
- 1594 79. Zheng, S.Q., Palovcak, E., Armache, J.-P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017).
1595 MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron
1596 microscopy. *Nature Methods* *14*, 331-332. 10.1038/nmeth.4193.
- 1597 80. Grant, T., and Grigorieff, N. (2015). Measuring the optimal exposure for single particle
1598 cryo-EM using a 2.6 Å reconstruction of rotavirus VP6. *eLife* *4*, e06980.
1599 10.7554/eLife.06980.
- 1600 81. Zheng, S., Wolff, G., Greenan, G., Chen, Z., Faas, F.G.A., Bárcena, M., Koster, A.J., Cheng, Y.,
1601 and Agard, D.A. (2022). AreTomo: An integrated software package for automated marker-
1602 free, motion-corrected cryo-electron tomographic alignment and reconstruction. *Journal*
1603 *of Structural Biology: X* *6*, 100068. 10.1016/j.jsbx.2022.100068.
- 1604 82. Kremer, J.R., Mastronarde, D.N., and McIntosh, J.R. (1996). Computer Visualization of
1605 Three-Dimensional Image Data Using IMOD. *Journal of Structural Biology* *116*, 71-76.
1606 10.1006/jsbi.1996.0013.
- 1607 83. Buchholz, T.-O., Jordan, M., Pigino, G., and Jug, F. (2019). Cryo-CARE: Content-Aware
1608 Image Restoration for Cryo-Transmission Electron Microscopy Data. 2019 IEEE 16th
1609 International Symposium on Biomedical Imaging (ISBI 2019), 502-506.
1610 10.1109/ISBI.2019.8759519.
- 1611 84. Liu, Y.-T., Zhang, H., Wang, H., Tao, C.-L., Bi, G.-Q., and Zhou, Z.H. (2022). Isotropic
1612 reconstruction for electron tomography with deep learning. *Nature Communications* *13*,
1613 6482. 10.1038/s41467-022-33957-8.
- 1614 85. Tegunov, D., and Cramer, P. (2019). Real-time cryo-electron microscopy data
1615 preprocessing with Warp. *Nature Methods* *16*, 1146-1152. 10.1038/s41592-019-0580-y.
- 1616 86. Scheres, S.H.W. (2012). RELION: Implementation of a Bayesian approach to cryo-EM
1617 structure determination. *Journal of Structural Biology* *180*, 519-530.
1618 10.1016/j.jsb.2012.09.006.
- 1619 87. Tegunov, D., Xue, L., Dienemann, C., Cramer, P., and Mahamid, J. (2021). Multi-particle
1620 cryo-EM refinement with M visualizes ribosome-antibiotic complex at 3.5 Å in cells.

- 1621 Nature Methods *18*, 186-193. 10.1038/s41592-020-01054-7.
- 1622 88. Meng, E.C., Goddard, T.D., Pettersen, E.F., Couch, G.S., Pearson, Z.J., Morris, J.H., and Ferrin,
1623 T.E. (2023). UCSF ChimeraX: Tools for structure building and analysis. *Protein Science* *32*,
1624 e4792. 10.1002/pro.4792.
- 1625 89. Kimanius, D., Forsberg, B.O., Scheres, S.H., and Lindahl, E. (2016). Accelerated cryo-EM
1626 structure determination with parallelisation using GPUs in RELION-2. *eLife* *5*, e18722.
1627 10.7554/eLife.18722.
- 1628 90. Zivanov, J., Nakane, T., Forsberg, B.O., Kimanius, D., Hagen, W.J., Lindahl, E., and Scheres,
1629 S.H. (2018). New tools for automated high-resolution cryo-EM structure determination in
1630 RELION-3. *eLife* *7*, e42166. 10.7554/eLife.42166.
- 1631 91. Roth, P., Ermel, U.H., Moser, D., Arctadius, G., Wehrheim, M., Scheffer, M.P., and Frangakis,
1632 A.S. (2025). ArtiaX: geometric models, camera paths and image processing tools. *Journal*
1633 *of Structural Biology* *217*, 108215. 10.1016/j.jsb.2025.108215.
- 1634 92. He, S., and Scheres, S.H.W. (2017). Helical reconstruction in RELION. *Journal of Structural*
1635 *Biology* *198*, 163-176. 10.1016/j.jsb.2017.02.003.
- 1636 93. Chaillet, M.L., van der Schot, G., Gubins, I., Roet, S., Veltkamp, R.C., and Förster, F. (2023).
1637 Extensive Angular Sampling Enables the Sensitive Localization of Macromolecules in
1638 Electron Tomograms. *International Journal of Molecular Sciences* *24*, 13375.
1639 10.3390/ijms241713375.
- 1640 94. Moebel, E., Martinez-Sanchez, A., Lamm, L., Righetto, R.D., Wietrzynski, W., Albert, S.,
1641 Larivière, D., Fourmentin, E., Pfeffer, S., Ortiz, J., et al. (2021). Deep learning improves
1642 macromolecule identification in 3D cellular cryo-electron tomograms. *Nature Methods*
1643 *18*, 1386-1394. 10.1038/s41592-021-01275-4.
- 1644 95. Lamm, L., Zufferey, S., Righetto, R.D., Wietrzynski, W., Yamauchi, K.A., Burt, A., Liu, Y.,
1645 Zhang, H., Martinez-Sanchez, A., Ziegler, S., et al. (2024). MemBrain v2: an end-to-end
1646 tool for the analysis of membranes in cryo-electron tomography.
1647 10.1101/2024.01.05.574336.
- 1648 96. Manner, A., and Islinger, M. (2023). Isolation of Mammalian Peroxisomes by Density
1649 Gradient Centrifugation. In *Peroxisomes: Methods and Protocols*, M. Schrader, ed.
1650 (Springer US), pp. 1-12.
- 1651 97. Manner, A., and Islinger, M. (2017). Isolation of Peroxisomes from Rat Liver and Cultured
1652 Hepatoma Cells by Density Gradient Centrifugation. In *Peroxisomes: Methods and*
1653 *Protocols*, M. Schrader, ed. (Springer), pp. 1-11.
- 1654 98. Kimanius, D., Dong, L., Sharov, G., Nakane, T., and Scheres, S.H.W. (2021). New tools for
1655 automated cryo-EM single-particle analysis in RELION-4.0. *The Biochemical Journal* *478*,
1656 4169-4185. 10.1042/BCJ20210708.
- 1657 99. Rohou, A., and Grigorieff, N. (2015). CTFIND4: Fast and accurate defocus estimation from
1658 electron micrographs. *Journal of Structural Biology* *192*, 216-221.
1659 10.1016/j.jsb.2015.08.008.
- 1660 100. Zivanov, J., Nakane, T., and Scheres, S.H.W. (2019). A Bayesian approach to beam-induced
1661 motion correction in cryo-EM single-particle analysis. *IUCrJ* *6*, 5-17.
1662 10.1107/S205225251801463X.
- 1663 101. Rosenthal, P.B., and Henderson, R. (2003). Optimal determination of particle orientation,
1664 absolute hand, and contrast loss in single-particle electron cryomicroscopy. *Journal of*

- 1665 Molecular Biology *333*, 721-745. 10.1016/j.jmb.2003.07.013.
- 1666 102. Sanchez-Garcia, R., Gomez-Blanco, J., Cuervo, A., Carazo, J.M., Sorzano, C.O.S., and
1667 Vargas, J. (2021). DeepEMhancer: a deep learning solution for cryo-EM volume post-
1668 processing. *Communications Biology* *4*, 1-8. 10.1038/s42003-021-02399-1.
- 1669 103. Tan, Y.Z., Baldwin, P.R., Davis, J.H., Williamson, J.R., Potter, C.S., Carragher, B., and Lyumkis,
1670 D. (2017). Addressing preferred specimen orientation in single-particle cryo-EM through
1671 tilting. *Nature Methods* *14*, 793-796. 10.1038/nmeth.4347.
- 1672 104. Punjani, A., Rubinstein, J.L., Fleet, D.J., and Brubaker, M.A. (2017). cryoSPARC: algorithms
1673 for rapid unsupervised cryo-EM structure determination. *Nature Methods* *14*, 290-296.
1674 10.1038/nmeth.4169.
- 1675 105. Bepler, T., Morin, A., Rapp, M., Brasch, J., Shapiro, L., Noble, A.J., and Berger, B. (2019).
1676 Positive-unlabeled convolutional neural networks for particle picking in cryo-electron
1677 micrographs. *Nature Methods* *16*, 1153-1160. 10.1038/s41592-019-0575-8.
- 1678 106. Punjani, A., Zhang, H., and Fleet, D.J. (2020). Non-uniform refinement: adaptive
1679 regularization improves single-particle cryo-EM reconstruction. *Nature Methods* *17*,
1680 1214-1221. 10.1038/s41592-020-00990-8.
- 1681 107. He, J., Li, T., and Huang, S.-Y. (2023). Improvement of cryo-EM maps by simultaneous
1682 local and non-local deep learning. *Nature Communications* *14*, 3217. 10.1038/s41467-
1683 023-39031-1.
- 1684 108. Jamali, K., Käll, L., Zhang, R., Brown, A., Kimanius, D., and Scheres, S.H.W. (2024).
1685 Automated model building and protein identification in cryo-EM maps. *Nature* *628*, 450-
1686 457. 10.1038/s41586-024-07215-4.
- 1687 109. Xu, K., Wang, Z., Shi, J., Li, H., and Zhang, Q.C. (2019). A²-Net: Molecular Structure
1688 Estimation from Cryo-EM Density Volumes. 10.48550/arXiv.1901.00785.
- 1689 110. Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of
1690 Coot. *Acta Crystallographica Section D: Biological Crystallography* *66*, 486-501.
1691 10.1107/S0907444910007493.
- 1692 111. Afonine, P.V., Poon, B.K., Read, R.J., Sobolev, O.V., Terwilliger, T.C., Urzhumtsev, A., and
1693 Adams, P.D. (2018). Real-space refinement in PHENIX for cryo-EM and crystallography.
1694 *Acta Crystallographica. Section D, Structural Biology* *74*, 531-544.
1695 10.1107/S2059798318006551.
- 1696 112. Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J.,
1697 Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive
1698 Python-based system for macromolecular structure solution. *Acta Crystallographica*
1699 *Section D: Biological Crystallography* *66*, 213-221. 10.1107/S0907444909052925.
- 1700 113. Williams, C.J., Headd, J.J., Moriarty, N.W., Prisant, M.G., Videau, L.L., Deis, L.N., Verma, V.,
1701 Keedy, D.A., Hintze, B.J., Chen, V.B., et al. (2018). MolProbity: More and better reference
1702 data for improved all-atom structure validation. *Protein Science: A Publication of the*
1703 *Protein Society* *27*, 293-315. 10.1002/pro.3330.
- 1704 114. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and
1705 Ferrin, T.E. (2004). UCSF Chimera--a visualization system for exploratory research and
1706 analysis. *Journal of Computational Chemistry* *25*, 1605-1612. 10.1002/jcc.20084.
- 1707 115. Schrödinger, L. (2015). The PyMOL Molecular Graphics System, Version 3.0.
- 1708 116. Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A., Ronneberger, O.,

- 1709 Willmore, L., Ballard, A.J., Bambrick, J., et al. (2024). Accurate structure prediction of
1710 biomolecular interactions with AlphaFold 3. *Nature* *630*, 493–500. 10.1038/s41586-024-
1711 07487-w.
- 1712 117. Wang, X., Xu, B.-L., and Chen, X.-W. (2021). Acute gene inactivation in the adult mouse
1713 liver using the CRISPR-Cas9 technology. *STAR Protocols* *2*, 100611.
1714 10.1016/j.xpro.2021.100611.
- 1715 118. Weerapana, E., Wang, C., Simon, G.M., Richter, F., Khare, S., Dillon, M.B.D., Bachovchin,
1716 D.A., Mowen, K., Baker, D., and Cravatt, B.F. (2010). Quantitative reactivity profiling predicts
1717 functional cysteines in proteomes. *Nature* *468*, 790–795. 10.1038/nature09472.
- 1718 119. Eastman, P., Swails, J., Chodera, J.D., McGibbon, R.T., Zhao, Y., Beauchamp, K.A., Wang,
1719 L.-P., Simmonett, A.C., Harrigan, M.P., Stern, C.D., et al. (2017). OpenMM 7: Rapid
1720 development of high performance algorithms for molecular dynamics. *PLOS*
1721 *Computational Biology* *13*, e1005659. 10.1371/journal.pcbi.1005659.
- 1722 120. O'Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., and Hutchison, G.R.
1723 (2011). Open Babel: An open chemical toolbox. *Journal of Cheminformatics* *3*, 33.
1724 10.1186/1758-2946-3-33.
- 1725 121. Maier, J.A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K.E., and Simmerling, C.
1726 (2015). ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters
1727 from ff99SB. *Journal of Chemical Theory and Computation* *11*, 3696–3713.
1728 10.1021/acs.jctc.5b00255.
- 1729 122. Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., and Klein, M.L. (1983).
1730 Comparison of simple potential functions for simulating liquid water. *The Journal of*
1731 *Chemical Physics* *79*, 926–935. 10.1063/1.445869.
- 1732 123. Case, D.A., Aktulga, H.M., Belfon, K., Cerutti, D.S., Cisneros, G.A., Cruzeiro, V.W.D.,
1733 Forouzesh, N., Giese, T.J., Götz, A.W., Gohlke, H., et al. (2023). AmberTools. *Journal of*
1734 *Chemical Information and Modeling* *63*, 6183–6191. 10.1021/acs.jcim.3c01153.
- 1735 124. Wei, D., Huang, X., Qiao, Y., Rao, J., Wang, L., Liao, F., and Zhan, C.-G. (2017). Catalytic
1736 Mechanisms for Cofactor-Free Oxidase-Catalyzed Reactions: Reaction Pathways of
1737 Uricase-Catalyzed Oxidation and Hydration of Uric Acid. *ACS Catalysis* *7*, 4623–4636.
1738 10.1021/acscatal.7b00901.
- 1739 125. Neese, F. (2012). The ORCA program system. *WIREs Computational Molecular Science* *2*,
1740 73–78. 10.1002/wcms.81.
- 1741 126. Neese, F. (2018). Software update: the ORCA program system, version 4.0. *WIREs*
1742 *Computational Molecular Science* *8*, e1327. <https://doi.org/10.1002/wcms.1327>.
- 1743 127. Bannwarth, C., Caldeweyher, E., Ehlert, S., Hansen, A., Pracht, P., Seibert, J., Spicher, S., and
1744 Grimme, S. (2021). Extended tight-binding quantum chemistry methods. *WIREs*
1745 *Computational Molecular Science* *11*, e1493. 10.1002/wcms.1493.
- 1746 128. Bannwarth, C., Ehlert, S., and Grimme, S. (2019). GFN2-xTB—An Accurate and Broadly
1747 Parametrized Self-Consistent Tight-Binding Quantum Chemical Method with Multipole
1748 Electrostatics and Density-Dependent Dispersion Contributions. *Journal of Chemical*
1749 *Theory and Computation* *15*, 1652–1671. 10.1021/acs.jctc.8b01176.
- 1750 129. Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H.,
1751 Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., et al. (2007). Clustal W and Clustal X version
1752 2.0. *Bioinformatics (Oxford, England)* *23*, 2947–2948. 10.1093/bioinformatics/btm404.

- 1753 130. Robert, X., and Gouet, P. (2014). Deciphering key features in protein structures with the
1754 new ENDscript server. *Nucleic Acids Research* *42*, W320-W324. 10.1093/nar/gku316.
- 1755 131. Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., and Madden,
1756 T.L. (2009). BLAST+: architecture and applications. *BMC bioinformatics* *10*, 421.
1757 10.1186/1471-2105-10-421.
- 1758 132. Goldfarb, T., Kodali, V.K., Pujar, S., Brover, V., Robbertse, B., Farrell, C.M., Oh, D.-H.,
1759 Astashyn, A., Ermolaeva, O., Haddad, D., et al. (2025). NCBI RefSeq: reference sequence
1760 standards through 25 years of curation and annotation. *Nucleic Acids Research* *53*, D243-
1761 D257. 10.1093/nar/gkae1038.
- 1762 133. Edgar, R.C. (2004). MUSCLE: multiple sequence alignment with high accuracy and high
1763 throughput. *Nucleic Acids Research* *32*, 1792-1797. 10.1093/nar/gkh340.
- 1764 134. Hinchliff, C.E., Smith, S.A., Allman, J.F., Burleigh, J.G., Chaudhary, R., Coghill, L.M., Crandall,
1765 K.A., Deng, J., Drew, B.T., Gazis, R., et al. (2015). Synthesis of phylogeny and taxonomy into
1766 a comprehensive tree of life. *Proceedings of the National Academy of Sciences* *112*,
1767 12764-12769. 10.1073/pnas.1423041112.
- 1768 135. Michonneau, F., Brown, J.W., and Winter, D.J. (2016). rotl: an R package to interact with
1769 the Open Tree of Life data. *Methods in Ecology and Evolution* *7*, 1476-1481.
1770 10.1111/2041-210X.12593.
- 1771 136. Xu, S., Li, L., Luo, X., Chen, M., Tang, W., Zhan, L., Dai, Z., Lam, T.T., Guan, Y., and Yu, G.
1772 (2022). Ggtree: A serialized data object for visualization of a phylogenetic tree and
1773 annotation data. *iMeta* *1*, e56. 10.1002/imt2.56.
- 1774